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Bioinformatics is a subfield in computational science that is principally focused on developing 
methods and performing data analytics in the areas of proteomics and genomics.  In this thesis I 
draw a link between proteomics and genomics by focusing on the regulation patterns of 
glycosyltransferase (GT) genes in breast cancer cell line following the treatment with a large set 
of Food and Drug Administration (FDA) approved drugs. This is based on the understanding that 
aberrant glycosylation in breast cancer tumours stem from altered GT gene expression. 
A major goal of genomic research is the identification of genes that have been differentially 
expressed under abnormal conditions. A gene expression profile provides a snapshot of the 
transcriptional level of a cell. A comparative gene expression profile between a diseased and 
normal state can be used to map out the regulatory mechanisms of disease. In this thesis, the results 
of Microarray experiments on MCF-7 human breast cancer cell-lines are analysed using statistical 
and computational tools to identify differentially expressed genes. 
Here a bioinformatics analysis of the regulation of GT gene expressions was performed to identify 
a set of glycosylation related genes with the aim of making an inference about their biological 
functions. A set of raw gene expression profiles from MCF-7 human breast cancer cell-line treated 
with different therapeutic drugs were obtained from the Connectivity Map (CMap) database. 
Initially 7,000 gene expression profiles were used and these were treated by 1,309 different FDA-
approved drugs. The number of genes initially was counted up to 22,000. Using the Bioconductor 
open source software in R statistical programming environment a statistical differential expression 
analysis followed by several data filtering and pre-processing steps were performed to identify up 
and down regulated GT genes using. Using non-parametric rank sum meta-analysis three cancer 
drugs and two non-cancer drugs were identified as effective agents able to control the 
transcriptional regulatory state of GT genes. 
The study concluded by employing co-expression gene module analysis using the Weighted Gene 
Co-Expression Network Analysis (WGCNA) package on each of the cancer and non-cancer drug 
treatments. The gene modules discovered from the analysis were used to perform gene ontology 
enrichment analysis to identify the biological functions where they were significantly enriched in. 
The co-expression modules where GT genes have been down regulated by the drugs, were 
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involved in processes such as Wnt signalling and cell surface pattern recognition receptor 
signalling important for cancer development. Immune response and apoptotic processes in the cell 
were identified from co-expression modules where GT genes were up regulated. This key finding 
that the GT gene expressions are markers for treatment analysis points to their use in drug 
development studies. The second more direct finding is that non-breast cancer specific FDA-
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1 COMPUTATIONAL SCIENCE AND BIOINFORMATICS 
 
1.1 Introduction 
Computational Science by its definition is a multidisciplinary field that incorporates advanced 
computing power and numerical analytics capabilities to solve complex scientific problems. The 
recent advancement in computing power and development of methodologies have radically 
changed the way how we collect complex high-dimensional data. Large data sets collected using 
advanced computing power have benefited research across all computational science that include 
computational biology where the focus is the development of models for molecular biology and 
the use of data analytics for genomics. Large public databases have been created to store high-
dimensional data often making these publicly available. The availability of large databases enabled 
the participation of a community of researchers, that develop tools for analysis and explore the 
data sets so making meaningful scientific contribution unencumbered by outdated traditional tools 
of a given field. (Peng, 2011) 
The advancement of computational science tools has contributed immensely to the development 
of modern biology. Many aspects of biological research incorporate mathematical, statistical 
models that have been derived from and computational methods that store, exploit, analyse 
massive amount of biological data for the purpose of answering fundamental biological questions. 
Regardless of whether the problem is simple or complex, the computational tools and 
mathematical concepts have become integral to modern biological research. 
Bioinformatics is an interdisciplinary field that implements statistical and computer science 
methods to biology. Bioinformatics recently gained its popularity because of the unprecedented 
amounts of biological data generated from advanced genomic methods, a rapid increase in 
computing powers and the development of analytics tools. Developing and using computational 
tools in molecular biology requires knowledge from a wide range of disciplines including 
mathematics, statistics, and information technology. This overlap of the computer and 
mathematical science tools applied to the domain science of molecular biology came to be known 
as bioinformatics. Computers are used to store, retrieve, manipulate, and distribute 
macromolecular information on biomolecules DNA, RNA, proteins and now more recently 
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Domain Scientific Field 
glycans (Barnett, Aoki-Kinoshita, & Naidoo, 2016). Because genomes are made from simple four 
letter alphabets. In the field of genomics data analysis, the computational routines traditionally 
used for text analysis can be transplanted. Complex methods can be assembled into bioinformatics 
analytic pipelines, making data mining in genomics easily accessible to mathematical novices. 















Figure 1.1 Components of computational science that incorporates mathematics, statistics, computer 
science and domain scientific fields. When the focus of the domain scientific field is uniquely from 
molecular biology and genomics, the combination is called bioinformatics. 
 
Bioinformatics is often referred to as computational biology, but the two fields are different in 
terms of biological problems dealt with. In bioinformatics, the topics focused are usually in 
sequence, structural, and functional analysis of genes and genomes and the corresponding product 
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known as proteins. Computational biology covers all biological areas that involve computation, 
for instance, population dynamics, phylogenetic, behavioural studies etc. (Xiong, 2006) Although 
the two terms have distinct characteristics, there are still many significant overlaps and activities 
at their interface. (Rao, Das, Rao, & Srinubabu, 2008) Ultimately the goals of bioinformatics are 
to utilize new technologies to better understand cells and their functions at a molecular level. 
(Xiong, 2006) From functional genomics to molecular sequence analysis and structural 
bioinformatics, this new and exciting sub-field of computational science have several aims. First, 
to organize and store biological data which can be accessed by other researchers in the field to 
conduct experiments following their unique protocols and submit new entries. Second, to develop 
efficient tools that will aid researche with their data mining and analysis activities. Third, use the 
available data to perform high-throughput analysis and biologically interpret meaningful results. 
Fourth, to aid the researchers in pharmaceutical industries to design and develop novel drugs for 
deadly diseases. (Rao et al., 2008) Before a deeper scope of bioinformatics can be explained, the 
next few paragraphs will cover topics including, big data in biology and recent next-generation 
sequencing techniques. Also, critical role of bioinformatics in the current setup of clinical research 
will be discussed. 
 
1.2 Big data in biology 
With the advent of high-throughput genomics and technologies, biologists have joined the big data 
club. (Marx, 2013) The new technologies allow biologists to generate enormous amounts of data 
in a cost-effective manner and this low-cost data generated, led to a big data era in biology. The 
data generated range from genomic sequence to images of physiological structures and in between 
the two types of data, factors such as mRNA expression, transcription factor binding, protein 
expression are measured as explained by the central dogma of molecular biology. (Gesing, Connor, 
& Taylor, 2015) Following on Human Genome Project that took 15 years and over $2 billion to 
complete, the Genome Analyzer was launched by Solexa, a biotechnology firm (now Illumina) in 
2006. Next-generation instruments such as Genome Analyzer has revolutionized the genomics 
field in that, it could do the same task of sequencing the genome in less than 3 days for less than 
$1000 (Gesing et al., 2015) (Marx, 2013). 
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The next-generation sequencing (NGS) technologies have created various biological and clinical 
datasets. The Cancer Genome Atlas (TCGA) is a project initiated in 2005, supervised by National 
Cancer Institute’s Center for Cancer Genomics and the National Human Genome Research 
Institute (NHGRI) that contains publicly available dataset of somatic mutations, copy number 
variation, mRNA expression, protein expression, and histology slides for approximately 7,000 
human tumours (Gesing et al., 2015) (Tomczak, Czerwińska, & Wiznerowicz, 2015). 
Encyclopaedia of DNA elements (ENCODE) is a public research project launched by US NHGRI 
in 2003 that has generated more than 2,600 genomic datasets from sequencing methods such as 
ChIP-Seq, RNA-Seq, ChIA-PET and CAGE. With a quantitative increase in genomic data, there 
were needs for repositories to store the data to analyse them. The European Bioinformatics Institute 
(EBI) offers repositories that store biological data including genomic data. There are many 
publicly available databases that contain genomic data produced in the labs of individual 
researchers and the data was made available for reproducible research, when their publications 
were released. (Gesing et al., 2015) For instance, Gene Expression Omnibus (GEO) is a public 
repository that archives high throughput data such as microarray data and Array Express, is a 
public repository that contains 1.3 million gene expression data from more than 45,000 laboratory 
experiments. (Rustici et al., 2012) The NGS platforms have enabled the creation of such public 
databases. The next few paragraphs will discuss some aspects of NGS and its challenges. 
 
1.2.1 Next-generation sequencing 
The “first generation sequencing” techniques were initiated from Sanger’s sequencing method. 
(Sanger, Nicklen, & Coulson, 1977) The success of human genome project has led the researchers 
to identify genome sequences in other species as well and several years later, the next-generation 
sequencing (NGS) method, called “second generation sequencing” techniques have appeared that 
revolutionized biological research fields. (Metzker, 2010) The next-generation sequencing 
methods performed sequencing tasks much quicker and cheaper than conventional sequencing 
techniques. With these advantages of the methods, the NGS technologies have been widely used 
for many applications including, transcriptome profiling that sequences cDNA to get a sample’s 
RNA content, which has become the standard method for measuring RNA expression level (Xuan, 
Yu, Qing, Guo, & Shi, 2013) (Schuster, 2007) (Zhao, Fung-Leung, Bittner, Ngo, & Liu, 2014). 
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There are numerous NGS platforms to power biological research, including Roche/454 sequencing 
system, Illumina/Solexa and Life Technologies/SOLiD (Schuster, 2007) (Dillies et al., 2013). The 
technical details of these major NGS platforms can be found in (Metzker, 2010). Each platform 
has its own advantages and disadvantages and the performance of each sequencing platform is 
described in table 1.1 along with their pros and cons. 






































































































a) information is based on company sources and www.molecularecologist.com.  
The platforms presented in table 1.1 have error types such as substitution, indel, A-T bias and 
deletion with their respective error rates. These errors must be carefully assessed and corrected so 
the potential impact on downstream analysis can be minimized. (Xuan et al., 2013) 
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The Illumina’s platforms have been widely used for diverse experimental purposes because of 
large amount of read production per price, which is mostly desired feature for NGS platform. 
Analysing and interpreting NGS data accurately and efficiently is crucial to apply NGS 
technologies in personalized medicine and bioinformatics provides tools and analytical capabilities 
to translate the data for personalized clinical medicine. (Hong et al., 2013) 
 
1.2.2 Computational challenges 
A significant advance in biological research has been the large volumes of data produced at 
historically short experimental times forms NGS technologies. Analysing these volumes of data 
appeared at first as a computational challenge. NGS with its deep sequencing high throughput 
methods, generate hundreds of millions of short sequence reads (Xuan et al., 2013) requires data 
storing, transferring and analyses. The Illumina sequencing platform for example generates 400 
million reads (100 bp paired end reads) in one lane that is equivalent to 40 GB of data. A typical 
sequence data analysis utilizes a few hundred GBs of disk space, memory and requires processing 
on multi-CPU computer nodes. For instance in de novo assembly, AbySS genome assembly tool 
requires at least 150 GB disk space and 24 cores for sequence data obtained from a single lane 
whereas, Trinity genome assembly requires at least 200 GB of memory. The gene expression 
analysis using RNA-Seq for example, requires computer clusters with nodes that have several 
hundred GB of memory, 2x12core CPUs and Tb disk space making this a costly supercomputing 
environment for many small laboratories. (Liu, 2017) Thus, prior to making decision regarding 
which NGS platform to use, it is critical to consider data storage and memory requirements. (Hong 
et al., 2013) 
 
1.3 Trends in bioinformatics 
Since the completion of the human genome project, the paradigm has shifted to a post-genomic 
era with an availability of large scale genomic data for biomedical informatics research. (Knaup 
et al., 2004) The National Center for Biotechnology Information (NCBI) especially, has 
contributed greatly in maintaining and growing collection of databases of genetic sequence and 
protein data along with other bioinformatics databases and this has transformed a conventional 
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genomic research into a computational domain which has become indispensable in life science 
research. (Knaup et al., 2004) With this, bioinformatics currently has roles in numerous field of 
life sciences research. 
Drug discovery has largely benefited from bioinformatics approach. High-throughput experiments 
have characterized drug target and disease process at a molecular level. The availability of massive 
screening libraries and drug databases have led to an efficient lead identification stage of drug 
development. Computational reconstruction and characterization of molecular pathways of 
different diseases using high-throughput experiments have been promising in drug development. 
(Fischer, 2005) Using computational approaches, pharmaceutical companies were able to identify 
novel drug target, disease state and different pathways related to the disease. The bioinformatics 
approach played a key role in both lead drug identification and drug repurposing in pharmaceutical 
industries. (Knaup et al., 2004) As the field of disease genetics and pharmacogenetics evolve, with 
bioinformatics approach, it is anticipated to enhance the scientific understanding of relationship 
between disease susceptibility and drug response for developing a novel target therapy. (Rao et al., 
2008) 
 
1.3.1 Bioinformatics in clinical research 
The bioinformatics approach plays a significant role in identifying molecular pathways and 
mechanisms that are important in clinical research. Of particular relevance here are studies that 
focus on the role of carbohydrates in cancer. Recently, Dong et al (2017) have used powerful 
bioinformatics pipelines combined with immunohistochemistry (IHC) analysis to identify key 
genes that affect carbohydrate macromolecular structures implicated in the development of gastric 
cancer. In the post-genomic era, much attention has turned to post-translational modifications 
(PTMs) and the most common by far is glycosylation. (Kikuchi & Narimatsu, 2006) Of greater 
consequence is the knowledge that aberrant glycosylation in tumours (due to altered 
glycosyltransferase (GT) gene expression) plays an important role in the development of cancer. 
(Ashkani & Naidoo, 2016) 
(Dong et al., 2017) used genetic data for gastric cancer samples and healthy normal samples that 
are publicly available on the TCGA database (section 1.2) to perform differential gene expression 
analysis between the two samples with the aim of identifying GT genes that have been up and 
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down regulated. The expression pattern of the GT genes was examined to identify GT genes that 
could act as potential biomarkers. Their analysis revealed that Protein O-fucosyltransferase-1 
(POFUT1), that catalyses the addition of O-fucose to epidermal growth factor-like (EGF) repeats 
in endoplasmic reticulum, is over-expressed. The gene set enrichment analysis identified that 
POFUT1 gene was involved in cell cycles and cell carcinoma functions in gastric cancer. (Dong 
et al., 2017) Through immunohistochemical analysis, they verified that POFUT1 gene was 
identified in various tumour samples. It was expected from the study that knockdown of POFUT1 
gene could inhibit progression of gastric cancer and with this, they have concluded that this key 
GT gene could potentially be a biomarker for gastric cancer, though further investigations are 
needed. 
(Ashkani & Naidoo, 2016) have examined the expression profiles of GT genes to classify cancer 
types. In a pioneering use of TCGA database to analyse the relative expression profiles of 210 GT 
genes from 1,893 cancer samples they discovered that they were able to classify breast, ovarian, 
glioblastoma, kidney, colon and lung cancers as well as discover subtypes for them. The subtype 
discovery allows prognosis based on the role of glycosylation in different cancer types making 
possible a personalised treatment strategy for cancer patients. 
The few examples described above illustrate that bioinformatics methods provide a way to 
investigate the role of postgenomic events that could significantly contribute to a research into 
personalised treatment. 
 
1.4 Bioinformatics applications and methodologies 
There are two main foci in bioinformatics research. The first is the development of software, 
computational tools and databases for biological data. The second revolves around the applications 
of these tools and databases developed to gain biological insight not possible from singular 
experimental observations. The software development is based on implementing sophisticated 
statistical models and computational algorithms that can be used to create stable databases and 
perform accurate and fast analyses of biological data. The tools created are developed for 
application in three major research areas namely, sequence analysis, functional analysis and 
structural analysis. Often these three applications are combined to produce an integrated result. 
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For instance, the prediction of protein structure needs the results from sequence alignment analysis 
and cellular function prediction requires methods from all three areas. (Sensen, 2008) (Xiong, 2006) 
















Figure 1.2 Overview of an ecosystem of bioinformatics fields. Bioinformatics tools development 
becomes the foundational basis for other analyses. Three applications are: sequence, functional, 
structural analysis and the three applications have intrinsic connections between them. 
 
1.4.1 Sequence analysis 
Sequence analysis deals with DNA, RNA or peptides (protein) sequences to understand its features, 
function and structures. There are many applications of sequence analysis, for instance, one can 
identify sequence differences and variations such as single nucleotide polymorphism (SNP) to 
Sequence Analysis Functional Analysis Structural Analysis 
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acquire a genetic marker or one can compare different sequences to identify homologous sequence 
that displays sequence similarity. (Sensen, 2008) (Xiong, 2006) (Kapetanovic, Rosenfeld, & 
Izmirlian, 2004) Some of the popular methods for sequence comparison includes, local and global 










Figure 1.3 An example of pairwise sequence comparison methods. The global sequence alignment 
method looks at all the residues. The local alignment includes portions of residues of the two 
sequences that have the highest similarity. The pipe character ‘|’ indicates an identical residue. 
 
1.4.2 Functional analysis 
Areas of functional analysis includes, gene expression profiling, protein-protein interaction 
prediction, metabolic and functional pathway analysis etc. As an example, functionally important 
genes in a disease can be analysed using computational methods and statistical approaches to 
identify how many genes are expressed for a specific function. Once the expression patterns of the 
genes are identified, it is possible to select a few genes that have shown significant amount of 
regulation and the set of genes can then undergo enrichment and pathway analysis to associate 
them to specific biological functions in a cell. The results of gene regulation can be visualized in 












Figure 1.4 An example of methods in gene expression analysis. a) Gene expression patterns are 
visualized under the heatmap to identify up and down regulated genes. b) The identified up and down 
regulated genes from the heatmap undergo pathway and functional enrichment network analysis to 
associate the group of genes to a specific pathway and biological functions in a cell (Massimino, 2017). 
 
1.4.3 Structural analysis 
Finally, structural analysis includes protein and nucleic acid structure modelling and analysis, 
comparison, classification and prediction. Studies involving protein structure analysis are often 
collectively referred to as proteomics. Proteomics methods can be used to identify therapeutic 
targets, the development of biomarkers and an examination of protein alterations that is not 
possible to gauge from DNA translation. (Baxevanis & Ouellette, 2004) (Goeta, 2002) For instance, 
Protein Data Bank (PDB) is a popular crystallographic database for three-dimensional structural 
data of large biomolecules and various protein structures can be obtained. The protein structures 
obtained can be modelled by running different simulations of docking to identify its active sites 













Figure 1.5 An example of molecular docking of batumin antibiotics to staphylococcus aureus active 
site using Discovery Studio program developed from Accelrys. The program offers functionalities for 
molecular docking, protein-binding site properties and complex ab initio simulations and many more 
(Tikhvinskiy & Porozov, 2013). 
 
1.4.4 Biological databases 
Following the Human Genome Project, the introduction of Next-Generation Sequencing (NGS) 
methods led to an exponential growth in, genomic data. New efficient computational methods were 
needed to store and process the NGS generated data making a wide range of databases available 
to biologists to analyse and make discoveries from. The computerized archives offer a large 
quantity of structured and standardized data that are easily retrieved. (Goeta, 2002) (Xiong, 2006) 
Databases can be used to identify new connections for instance, raw sequences from a database 
can be compared using computational methods to identify homologous motifs or gene expression 
patterns of different samples can be compared to discover mechanisms for diseases. This type of 
database application is aptly named knowledge discovery. (Isewon, 2009) Currently a relational 
database is the most popular model. Typically, these can be created using a structured query 
language (SQL). (Sensen, 2008) Here a set of tables is used to organize data instead of using a 
single table with flat files. The relational database model offers great querying performance for 
large data sizes. Further, when different biological databases are interconnected, the entries from 
different databases can relate to each other which opens up another avenue to knowledge discovery 
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using information retrieval. The complexity of biomedical data is in the use of graph database as 
a replacement for relational database, such as platforms like Neo4J.  
 
1.4.5 Software development and statistical approaches 
The bioinformatician’s tasks includes, data storing, management and modelling. While the 
biological databases have been created (section 1.1.4) to address the data storing and management 
tasks, it is crucial to use efficient modelling methods to effectively analyse the vast amount of 
biological data. To accomplish this, statistical and computational methods must be incorporated to 
develop useful statistical and mathematical models embedded in bioinformatics software that 
facilitate data analytics. There are a number of programs developed for specific applications in 
bioinformatics. For instance, the Bioconductor project, which will be discussed in detail in chapter 
2, is an open-source software package developed to perform various genomic data analysis. The 
Bioconductor requires an R statistical programming environment making many useful statistical 
modelling techniques possible. (Gentleman et al., 2004) Machine Learning (ML) techniques and 
innovative deep learning methods have recently gained popularity amongst bioinformaticians. For 
instance, microarray data gene expression pattern identification, genetic network induction, 
classifier development for cancer subtype prediction and clustering of genes all use machine 
learning methods and the results are promising. (Ashkani & Naidoo, 2016) (Larranaga et al., 2006) 
(Min, Lee, & Yoon, 2017) Overall, bioinformatics software development using tailored 
computational algorithms and  rigorous statistical models transforms traditional analytical 
pipelines to efficiently accelerate biological data modelling and analysis. 
 
1.5 Limitations and issues in bioinformatics 
Although an informatics approach to analysing genomic data provides powerful pathways to 
discovery but it must be cautioned that an over-reliance on computational outputs without a clear 
understanding of the statistical methods underlying the techniques and the quality of data being 
analysed is foolhardy. A case in point is that poor quality data generated by NGS techniques can 
lead to a catastrophic misinterpretations. (Dillies et al., 2013) Before embarking on an extensive 
computational experiment, the raw data generated from NGS experiments must be evaluated to 
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uncover errors due to bias and/or noisy data. If these are not corrected or if erroneous raw data are 
used in the downstream analysis, the entire biological interpretation will be faulty. The 
computational algorithms are not always efficient and they could lead to false predictions. (Sensen, 
2008) (Baxevanis & Ouellette, 2004) (Xiong, 2006) Often sophisticated computational algorithms 
that generate accurate results are slow as they rely on the availability of large computing resources. 
Comparatively, faster algorithms are found to generate less accurate results. The novice 
practitioner may be faced with the dilemma faced with a choice of speed vs. accuracy. To 
overcome this pitfall, it is often recommended to perform the analysis using multiple pipelines, 
algorithms or programs. Multiple evaluations are then possible as the results generated from 
different methods can be compared. (Goeta, 2002) 
 
1.6 Aims and objectives 
The aim of this research was to identify and examine gene expression regulation of key 
glycosyltransferase (GT) genes and their associated biological functions with other genes from the 
MCF-7 human breast cancer cell line treated with therapeutic Food and Drug Administration (FDA) 
approved drugs. This required employing functional analysis methodologies (section 1.4.2). 
Moreover, a specific objective was to understand the role of carbohydrate related genes in breast 
cancer. This was done by investigating the effect of known drugs administered to cancer cell lines 
on the regulation of glycosyltransferase genes. 
The first methodological objective was to pre-process raw gene expression data retrieved from the 
Connectivity Map (CMap) database using standard microarray data analytics pipeline to generate 
a suitable expression matrix for statistical analysis. 
The second methodological objective was to perform differential gene expression analysis using 
LIMMA tool from Bioconductor project in R statistical computing environment and filter out GT 
genes for subsequent analysis. 
Following the methods employed above the third project objective was to select therapeutic drugs 
that contributes the most to the regulation of GT genes by performing meta-analysis that 
incorporates two-groups Wilcoxon rank sum test. Rank sum test is used to statistically test if the 
drug had significantly affected GT genes in comparison to non-GT genes. 
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Finally, the aim was to identify co-expression modules of gene expression data from selected drugs 
using the WGCNA clustering method and associate the co-expression modules to biological 
functions using a gene ontology enrichment analysis. Differentially expressed GT genes within the 
co-expression module were identified. The GT genes regulatory pattern and the involvement of 
GT genes in the co-expression modules with its associated biological function were used to gain 
insight into how carbohydrate related genes collaborate with other oncogenes to contribute to 
breast cancer progression. Further it was hoped to provide possible insight into the discovery of 
presently approved drugs that could be repurposed for breast cancer treatment. 
 
1.7 Thesis synopsis 
In Chapter 2, I discuss relevant bioinformatics gene expression methods, and how to utilize high-
throughput technologies such as microarray to examine and quantify gene expression of a sample. 
The biology underpinning a gene expression is briefly described. The bioinformatics workflow for 
microarray data analysis such as pre-processing, statistical methods, analytics environment and 
class discovery topics and methods such as WGCNA can be used to filter gene expression data. 
In Chapter 3, I discuss overview of the glycobiology of breast cancer. Molecular mechanisms in 
breast cancer and its treatment in the context of abnormal glycosylation in cancer is discussed. The 
role of carbohydrates, cellular function and regulation of glycosyltransferase (GT) genes are 
summarised as well. Literatures regarding the involvement of some of the most well-known GT 
genes in breast cancer is described. GT genes have roles in abnormal glycosylation which results 
in breast cancer and their functions and contributions to breast cancer will be analysed. 
In Chapter 4, I discuss how gene expression data for this research work was prepared using the 
techniques described in chapter 2. An overview of the Connectivity Map (CMap) is given and its 
database is explained along with research uses of CMap data. CMap Data cleaning and preparation 
will be done. A detailed information on therapeutic drugs used to treat the breast cancer cell line 
will be discussed. Several data pre-processing steps will be performed including, data quality 
checking, normalization, batch effect with principal component analysis and gene annotations. The 
prepared gene expression data can be used to perform further differential expression analysis. 
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Hence, the generation of suitable gene expression matrix for statistical analysis was the main goal 
of this chapter. 
In Chapter 5, I discuss statistical analyses of differentially expressed genes (DEGs) from the 
expression matrix generated in chapter 4. Several statistical analysis tools for gene expression such 
as LIMMA are described. LIMMA tool will be used to identify statistically significant 
differentially expressed GT genes and drugs that have significant effect on the regulation of GT 
genes will be selected. The resulting drug treated samples will further be analysed using WGCNA 
method to identify co-expression modules of genes from the treatment. Finally, Gene Ontology 
(GO) enrichment analysis will be performed to identify biological functions associated with co-
expression modules. The GT genes involved in each of the co-expression module will be identified 
and relate them to the biological functions for interpretation. In this way, the roles of GT genes in 
breast cancer and insight into how to design a novel drug can be obtained. 
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2 GENE EXPRESSION ANALYSIS TECHNIQUES 
 
2.1 Gene expression analysis overview 
The genomics research aims to study the genes, mutation, polymorphisms, and phylogenetic 
relationship of an organism from its original DNA sequences. One important area of genomics 
research is the analysis of transcriptional regulation of genes known as ‘gene expression’. An 
examination of gene expression pattern of genes, in response to number of clinical conditions, 
natural or toxic agents and biological processes at different times, can identify what genes are up 
and down regulated by the condition. Based on the up and down regulated gene patterns, the key 
genes involved in cellular functions can be identified. (Suárez, Burguete, & McLachlan, 2009) For 
instance, the key genes identified can be used to develop a novel biomarker, or they can be used 
as a specific drug target in certain diseases. The application of gene expression is countless and 
the insights it can provide are enormous. For this reason, a high-throughput microarray technology 
that simultaneously measures the expression levels of thousands of genes has been developed. 
Recently, a more powerful RNA-Seq technology was introduced in the biotech market, but the 
microarray technology has still shown promising results in the field of genomics research, 
particularly in the cancer research and it is expected that the gene expression profiling using the 
microarray will catalyse the development of personalised treatment strategies for cancer patients 
based on the classification of molecular subtypes. (Fan & Ren, 2006) (Wang, Gerstein, & Snyder, 
2009) As the amount of gene expression data generated from the microarray experiments is huge, 
the bioinformatics plays an essential role in acquiring, storing and analysing the data. There are a 
number of well-known bioinformatics tools already available to analyse the data generated in 
efficient ways and these tools are capable of dealing with messy biological data. 
In this chapter, gene expression techniques used to perform downstream analyses will be discussed. 
Initially, the central dogma of molecular biology is discussed to introduce the concept of gene 
expression and provide general background. Next, microarray experiment, a popular technique to 
measure gene expression is discussed in detail. Microarray experiment generate numerical 
expression matrix and techniques for data quality checking and various pre-processing techniques 
are discussed. Thereafter, the statistical methods for microarray data analysis is discussed together 
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with the necessary computing environments. Next, RNA-Seq, a more recent technology for 
transcriptome profiling will be introduced and the pros and cons of microarray and RNA-Seq 
platforms will be discussed. Finally, the gene ontology enrichment analysis that associates 
identified differentially expressed genes to its enriched biological functions will be discussed.  
 
2.2 Gene expression 
The process in which the information of genes is used to synthesize its functional product, a protein 
is called gene expression. Gene expression processes are mainly handled by transcription and 
translation steps in a cell. The regulation of gene expression process refers to the control of the 
amount of functional product of genes produced and this is vital to cells, as the cells can control 
the production of gene products to respond to external stimulus, adapt to different environments, 
repair from the cell damage and undergo various cellular differentiations and morphogenesis. The 
regulation of genes expression controls the structures and functions of a cell. (Sánchez & de Villa, 
2008) The next section covers the central dogma of molecular biology which describes the two-
steps process, transcription and translation that forms the basis of gene expression process.  
 
2.2.1 Central dogma of molecular biology 
Protein is a product of genes that performs essential functions and forms various structures in cells. 
Proteins do not self-assemble, but they need sets of instructions to assemble and the instructions 
for protein sequence, structure and functions are contained within DNA. The DNAs essentially 
contain the complete genetic instructions that describes the functions and structures of a cell, and 
moreover, an organism. (Sánchez & de Villa, 2008) The central dogma of molecular biology is an 
explanation of the flow of genetic instructions from DNA to proteins introduced by Francis Crick 
in 1958. (Crick, 1970). The idea is that the genes contain genetic instructions to synthesize proteins 
and this is done in three steps namely, transcription, splicing and translation.  
In eukaryotic cells, the DNA molecule is discovered in the form of a nucleoprotein complex named 
chromatin. Chromatin is a mass of genetic material composed of DNA and proteins that condense 
to form chromosomes during eukaryotic cell division. Chromatin is located in the nucleus of the 
cells. The primary function of chromatin is to compress the DNA into a compact unit that will be 
21 
 
less voluminous and can fit within the nucleus. Chromatin consists of complexes of small proteins 
known as histones and DNA. Histones help to organize DNA into structures called nucleosomes 
by providing a base on which the DNA can be wrapped around. A nucleosome consists of a DNA 
sequence of about 150 base pairs that is wrapped around a set of eight histones called an octamer. 
The nucleosome is further folded to produce a chromatin fibre. Chromatin fibres are coiled and 
condensed to form chromosomes. Chromatin makes it possible for a number of cell processes to 
occur including DNA replication, transcription, DNA repair, genetic recombination, and cell 
division. Chromatin can affect a gene’s availability for transcription.  
In transcription, a double stranded DNA unwinds, and each copy undergoes replication to produce 
identical copies of each helix. Each copies of helix are copied into a complementary mRNA helix. 
In splicing, the exons are joined together. Usually exons code for protein and the non-coding 
introns are removed by splicing. Proteins called transcription factors play a central role in 
regulating transcription. These proteins help determine which genes are active in each cell. For 
translation to happen, enzymes called RNA polymerase which makes a new RNA molecule from 
a DNA template must attach to the DNA of the gene. It attaches at the promoter. RNA polymerase 
can attach to the promoter only with the help of basal transcription factors. There are large class 
of transcription factors that control the expression of specific, individual genes. For instance, a 
transcription factor might activate only a set of genes needed in certain neurons. A transcription 
factor binds to DNA at a certain target sequence. Activators activate transcription by helping the 
general transcription factors or RNA polymerase bind to the promoter. Repressors represses 
transcription, for instance, they may get in the way of the basal transcription factors or RNA 
polymerase, making it so they can’t bind to the promoter or begin transcription. The transcription 
start site is the location where transcription starts and it is located at 5’-end of a gene sequence and 
the core promoter includes the transcription start sites (TSS). When RNA polymerase binds to a 
promoter sequence at the TSS, the transcription starts and RNA polymerase would use one of the 
DNA strands to make a new complementary RNA molecule. (Sandelin et al 2004).   
In translation, the amino acids are joined the form a sequence that results in protein. The amino 
acid sequences are determined by the order encoded in the mRNA known as a genetic code or a 










Figure 2.1 The schematic view of gene expression process based on the central dogma of molecular 
biology introduced by Francis Crick in 1958. The process starts with DNA replications and ends with 
translation that results in proteins (Crick, 1970). 
 
Traditionally it was believed that a single gene results in a single protein which in fact, was not 
true due to various modifications such as alternative splicing and post-translational modifications 
in which one gene can result in several proteins. Following on from the understanding of central 
dogma of molecular biology, it has become important for biologists to understand what and how 
much mRNA is around so that they could identify the specific genes that display such expression 
intensity. For this reason, to quantitatively measure thousands of gene expression from 
experiments simultaneously, a high-throughput microarray technology has been developed. (Faiz 
& Burgess, 2012) 
 
2.3 Microarray experiments and data analysis 
The term microarray was defined by (Choudhuri, 2004) as “a high-throughput assay system which 
utilizes spatially ordered discrete, high-density arrangement of biologically important entities 
immobilized on a solid platform”, where the entities usually are nucleic acids fragments, proteins 
carbohydrates etc. The study by (Pirrung, 2002) also defines microarray as “monolithic, flat 
surfaces that bear multiple probe sites, often hundreds and thousands, and each bear a reagent 
whose molecular recognition of a complementary molecule can lead to a signal that is detected by 
an imaging, most often fluorescence”. The first microarray was an oligonucleotide-based 
microarray called GeneChip introduced by Affymetrix in 1996 and several types of microarrays 
have been developed and commercialized. (Faiz & Burgess, 2012) (Pirrung, 2002) 
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There are mainly two types of microarray technologies used in the biomedical research based on 
the material used as probe. First type is a complementary DNA known as cDNA and the second 
type is oligonucleotide microarray as explained in the above paragraph. The two microarrays 
usually have different probe and different target preparation (figure 2.2). In cDNA microarray, the 
probes are polymerase chain reaction (PCR) fragments that are amplified from the specific target 
sequences or clones from a cDNA library. cDNA microarray typically has been useful in the 
identification heterologous genes across species. The oligonucleotide microarrays are typically 
smaller (length of oligonucleotide microarray denoted by “25-mer”) compared to the cDNA 
microarray (hundreds to thousands base pairs) and they do not utilize cDNA library, because their 
probes are synthesized on the chip and then immobilized on the platform. (Tarca, Romero, & 










Figure 2.2 The schematic overview of probe array and target preparation for (a) cDNA microarrays: 
this is the two-channel microarray and (b) high-density oligonucleotide microarrays: this is a single 
channel microarray (Tarca et al., 2006). 
 
Typically, the sample of DNA or RNA is separated from the biological sample goes through 
amplification. The samples are then labelled usually with the fluorescent dyes. Following the 
fluorescent labelling, the hybridization process happens between the complementary probes 
attached to the microarray surface and the isolated DNA or RNA samples. The microarray chips 
with hybridized double stranded molecules are rinsed to exclude non-specifically bounded 
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molecules and the fluorescent or radioactive images are recorded (known as image processing). 
The fluorescent images are produced by the label excitation by the laser scanner and they are 
captured by the camera. The fluorescent labelled hybridized image provides information about the 
locations of successful hybridization spot and the relative gene expression of a gene by displaying 
the intensity of the hybridized spot with specific probes. (Fan & Ren, 2006) (Pirrung, 2002) A 
higher intensity shows high gene expression level and the opposite is true as well. The microarray 
technologies thus, are capable of quantitatively measure thousands of gene expression levels 
simultaneously to examine the gene expression patterns after a specific type of experiments. 
Usually the gene expression of specific sequences is validated through RT-PCR. (Pirrung, 2002) 
Once, microarray experiments are performed, data must be analysed by incorporating several 











Figure 2.3 A schematic view of microarray data analysis processes. 
 
The next few paragraphs cover several available computational tools to perform microarray 
analysis and gene expression data pre-processing steps including data quality checks and 
normalization techniques to transform the raw gene expression data to a suitable format that can 
be used for subsequent statistical analysis. 
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2.3.1 Methods and software 
The growth of microarray applications in various research fields have increased the need for 
development of computational tools and analysis environment, new methods to model and analyse 
the data were required. The new tools were essential for processes such as obtaining and storing 
of the bulk of biological data generated. There are several commercial proprietary tools developed 
for bioinformatics analysis. These range from small software to much larger software for more 
complex data analysis such as Partek Genomics Suite that brings fast and optimized solutions for 
genomics data (Sánchez & de Villa, 2008). Commercial programs may have useful functions and 
tools optimized for biological the data, but they are usually very expensive, thus often an open 
source software may be the solution for bioinformaticians. There are obvious pros and cons of 
using an open source tools such as being prone to errors and not being maintained regularly, but 
open source software remains a good choice for biologists performing a gene expression analysis 
as there are several good open source software and supports available for this purpose. (Sánchez 
& de Villa, 2008) (Parmigiani, Garrett, Irizarry, & Zeger, 2003) The next few sections cover tools 
and analysis environment for gene expression analysis. 
 
2.3.1.1 R programming language 
R is a programming language designed for statistical computing and visualizations that is a free 
software supported by the R Foundation for Statistical Computing. The R programming language 
was created by Ross Ihaka and Robert Gentleman at the University of Auckland in New Zealand 
with the initial version release in 1995. It is available freely at https://www.r-project.org/. R has 
gained its popularity in the bioinformatics research areas due to a great support for statistical and 
graphical (for data visualizations) packages for complex biological data analysis, such as “ggplot2” 
and “dplyr” for visualizations and data manipulations respectively. (de Leeuw, 2009) R also 
supports object-oriented programming paradigm. R’s one of the biggest advantages may be that it 
has a well-established system for package creation. There is a good amount of support by the 
community to create, test and distribute packages for different purposes and there are many 
packages created and distributed for biological analyses too such as the Bioconductor Project. 




2.3.1.2 Bioconductor project 
The Bioconductor Project is an initiative for the collaborative development of computational 
biology and bioinformatics software. (Gentleman et al., 2004) The Bioconductor is an open source 
software project that provides a comprehensive support for genomic data analysis such as 
differential gene expression analysis and genome annotation etc. and it is based primarily on the 
R programming language. (Gentleman et al., 2004) One of the best approaches for genomics data 
analysis is incorporation of standard software with specific packages or libraries designed for 
microarray data analysis and the Bioconductor Project provides all the support for such purposes. 
The project (available at: https://www.bioconductor.org/) has grown extensively from 2001 and 
now, almost every microarray analysis technique has its own package. The R programming 
combined with the flexibility of the Bioconductor microarray analysis packages remain the chosen 
tool for statisticians and bioinformatician due to its capabilities to automate redundant analysis 
jobs in biological research and support for great visualizations and reporting tools. (Sánchez & de 
Villa, 2008) (Gentleman et al., 2004) 
 
2.3.2 Pre-processing steps 
Microarray data pre-processing is a crucial step that must be completed before proceeding with an 
actual statistical data analysis to remove any systematic variations and biases. (Allison, Cui, Page, 
& Sabripour, 2006) There are mainly two steps in microarray pre-processing. First, the data quality 
must be checked to determine if the data can be considered reliable. A typical high-throughput 
microarray data consist of huge numerical matrices and it is difficult to detect all the problems in 
the matrices by visual inspection, thus a specific data quality control procedure must be followed. 
Second, the quality-checked data must undergo normalization to correct for any technical artefacts. 
There are many normalization techniques developed and tested and selecting a specific 
normalization technique for microarray data analysis is crucial. (Sánchez & de Villa, 2008) 
 
2.3.2.1 Data quality checks 
The data quality check looks to examine and determine if the microarray data is reliable for 
subsequent statistical analysis. The quality assessment usually involves image analysis and several 
plots visualizations to detect any unreliable sources. Images of raw microarray data can be valuable 
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to detect irregular patterns such as scratches, rings, bubbles, shadows and lines. Sometimes it is 
difficult to check the images of all the raw microarray data, so methods such as signal-to-noise 
histograms or density plots of arrays that looks for significant multi-modality in the distribution 
can be used to detect poor quality arrays. RNA degradation plot can also be used to detect 
unreliable sources in the arrays. (Gillespie, Lei, Boys, Greenall, & Wilkinson, 2010) The figure 















Figure 2.4 An example of diagnostic plots for the microarray samples. a) Density plot that checks for 
multi-modality. b) RNA degradation plot to detect the quality of RNA samples used to prepare 
microarray data (Sánchez & de Villa, 2008). 
 
2.3.2.2 Normalization techniques 
After checking the data quality, different technical artefacts must be removed, and the 




to adjust some individual hybridization intensities to balance them, from which meaningful 
biological analysis can continue. Typically, microarray analysis aims to explain the source of 
variation between RNA populations under different conditions (usually between diseased and 
normal) using their expression, to identify a gene or genes that may cause disease. The expression 
level observed, does not only include biological variation but it also includes variations introduced 
during sample preparation, array manufacture and the processing of arrays such as hybridization 
for example. These technical variation or biases, must be removed by data normalization to 
compare data from different arrays and different sources. (Irizarry et al., 2003) There are many 
normalization techniques developed for this purpose and some important normalizations are 
discussed in the next few sections. 
2.3.2.2.1 Robust-multi array (RMA) 
In high-density oligonucleotide microarrays provided by Affymetrix GeneChip, the most 
frequently used method is Robust-Multichip Average (RMA) normalization. The oligonucleotide 
microarray probes consist of 25 base pairs in length with two types of probes namely, perfect 
match (PM) and mismatch (MM). The PM probes are reference probes that match the target 
sequence perfectly, but MM probes differ from the reference sequence by one single base and the 
intensities from each probe in a probe-set are combined to provide an expression measure. (Irizarry 
et al., 2003) (Bolstad, Irizarry, Åstrand, & Speed, 2003) In RMA normalization, a robust average 
of log2 background corrected PM intensities are used to make an estimate. The RMA normalization 
typically consists of 3 steps. First, a probe level background adjustment is made. Second, quantile 
normalization is made and lastly, summarization of all the values of probe related to one gene is 
made. There are many other normalization methods such as MAS5.0 developed by the Affymetrix 
manufacturer, but RMA normalization is preferred as they tend to generate less false positives. 
(Sánchez & de Villa, 2008) 
 
2.3.2.2.2 Quantile normalization 
In some microarray experiments, numerical gene matrices from different arrays are combined. For 
example, an experiment could contain Affymetrix arrays, HG-U133A and HT_HG-U133A and 
before the gene matrices from two different arrays can be combined for a bigger analysis, a method 
must exist to remove a noise derived from different physical arrays. Quantile normalization 
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(typically known as within slides normalization) is a method that achieves consistency between 
different arrays by making the distribution of probe intensities from different arrays uniform. 
(Sánchez & de Villa, 2008) (Irizarry et al., 2003) The boxplots are usually a very useful tool to 
visualize the effects of different normalization methods on the microarray data. 
 
2.3.2.3 Batch effects 
Once the data quality has been checked and technical artefacts are removed through normalization, 
it is important to check if the transcriptomic dataset contains any batch effect. Batch effects are the 
systematic errors introduced when samples are handled in multiple batches in a laboratory. 
Through careful design of experiments, batch effects may be reduced, but it cannot be eliminated 
unless the whole experiment was done in a single batch. (Chen et al., 2011) Batch effects in gene 
expression from the vast expression dataset may typically come from cell culture conditions and 
other uncontrollable variables such as chip type, platform, laboratory, technicians, storage and 
shipment conditions and protocols etc. and these factors confound gene expression variation due 
to an actual experimental condition for instance, the test of different drugs. This technical bias 
must be detected and removed otherwise this could have a serious effect on downstream 
microarray analysis results. (Reese et al., 2013) There are number of methods available to adjust 
for batch effects. 
A common method to detect batch effects in the transcriptomic data is the use of principle 
component analysis (PCA), an unsupervised learning algorithm used for dimensionality reduction 
and interpretation. PCA aims to identify the ‘combination of conditions that explain the greatest 
variation in the data’ (Yang et al., 2008). Typically, in PCA, the first two principle components 
with each sample coloured according to their respective batch number are plotted. If there is a clear 
separation of colours in the PCA plot, it probably indicates that the greatest variation comes from 
the batch effect and this must be removed. Once the batch effects are removed and the first 
principle components are re-plotted, the color-coded samples will cluster together, since now the 
greatest source of variation in gene expression may be anything else than the batch effects. (Reese 
et al., 2013) There are several ways to remove the batch effects, but one of the most popular 
methods is to utilize the ‘ComBat’ function available from the SVA package through the 
Bioconductor Project (section 2.3.1.2). The ‘ComBat’ function requires a batch vector as one of 
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its input and it will return a batch-corrected gene expression matrix. After the global normalization 
of the expression data, detection and the removal of batch effects is a crucial step in building a 
gene expression matrix that can be used for downstream statistical analysis and this step should 
never be underestimated. 
 
2.3.2.4 Gene annotation 
The numerical gene matrix obtained from the pre-processing, typically has the Affymetrix probe 
set identifiers in its rows and the sample’s experimental condition in its columns. The probe set 
identifiers must be mapped with their corresponding gene symbols for the identification of 
differentially expressed genes during statistical analysis and visualizations. A well-known 
bioinformatics packages from the Bioconductor Project (section 2.3.1.2) are usually utilized for 
gene symbol annotations. The packages such as, “hgu133a.db” and “hthgu133a.db” can be used 
to annotate the Affymetrix probe set identifiers of chips like HG-U133A and HT_HG-U133A. 
Once the probe identifiers are mapped with their corresponding gene symbols or ENTREZ gene 
identifiers for subsequent statistical analysis to identify genes of interest or to perform gene 
ontology analysis. (Gentleman et al., 2004) 
 
2.3.3 Differential expression statistical analysis 
After microarray data has been pre-processed following several standard procedures, an important 
statistical question is to detect and select genes that are differentially expressed between the 
experimental and control samples. When designing a microarray data analysis experiment, it is 
crucial to consider the presence of biological replicates, sometimes known as within-array 
replications. Biological replicates are samples of same genetic material that have been tested with 
a specific experimental condition, that are expected to show similar gene expression pattern. 
Biological replicates are used in microarray data analysis to improve the precision of statistical 
methods designed to identify differentially expressed genes. (Fan & Ren, 2006) 
Differential expression analysis is a statistical inference method to identify genes whose 
expression levels are significantly different between two groups of experiments. (Selvaraj & 
Natarajan, 2011) The analysis starts with selection of proper statistical test. Some of the most 
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widely used methods include, Significance Analysis of Microarrays (SAM), one-sample and two-
sample t test, F-statistics and an empirical Bayes method. (Fan & Ren, 2006) In the next few 
sections, one of the most popular methods for microarray differential expression analysis is 
described. 
 
2.3.3.1 Linear modelling for microarrays 
LIMMA is a popular Bioconductor software package that provides comprehensive set of tools for 
microarray gene expression analysis and the package has incorporated several statistical principles 
for large scale expression analysis. Initially, several matrices of gene expression values are created 
known as design matrix and contrast matrix that represent RNA targets and experimental 
conditions respectively. The rows of matrices usually represent a gene and the columns represent 
the experimental conditions. Once, experimental matrices are constructed, a linear model is fitted 
to each row of gene expression data to compute test statistics including t-statistics and F-statistics. 
(Selvaraj & Natarajan, 2011) In this way, a complex experimental designs and hypotheses can be 
tested and the strength between the gene-wise models are borrowed to increase the reliability of 
statistical test even with the small number of samples. (Smyth, Ritchie, Thorne, & Wettenhall, 













Figure 2.5 Schematic of major statistical principles of LIMMA analysis. Initially, for each gene g, its 
gene expression values and a design matrix X relate to coefficients of interest (βg). Typically, 
empirical Bayes methods are used to obtain posterior variance estimator (s2*g) to facilitate gene-wise 
information borrowing process. LIMMA also utilizes observation weight to allow for data quality 
variations, variance modelling to count for technical or biological differences that are present and 
pre-processing methods to remove biases and noises present in data. The combination of these 
statistical principles all contribute to the improvement of statistical inference for genes and gene sets 
in microarray data analysis with small number of samples (Smyth et al., 2005). 
 
After linear model fitting, the standard errors are moderated using a simple parametric empirical 
Bayes model that borrows strength between genes to moderate the residual variances. This method 
after linear fitting computes a moderated t-statistics and log-odds of differential expression for 
each contrast of each gene. Empirical Bayes method that incorporate posterior variance estimators 
effectively increased the degrees of freedom in which the gene-wise variances are estimated, and 
it has been proved that this method was particularly useful in microarray data analysis with small 
sample size in terms of reliable statistical inference. (Smyth et al., 2005) (Reiner, Yekutieli, & 
Benjamini, 2003) Empirical Bayes also computes a moderated F-statistics that combines the t-
statistics for all the contrasts for each gene into an overall test of significance for the gene. 
Typically, the moderated F-statistics tests for non-zero in contrasts for the gene and the p-values 
are generated. In an experiment with a numerous contrast, it is usually recommended to select 
differentially expressed genes based on moderated F-statistics and significance of the contrasts for 
the genes. This is especially advantageous as the number of tests can be cut down to reduce the 
amount of adjustment for multiple testing. (Smyth et al., 2005) In overall, LIMMA package 
available through Bioconductor project provide a comprehensive set of powerful tools that can be 
used to detect differentially expressed genes in reliable manner with improved statistical power 
and accuracy. 
 
2.3.3.2 False discovery rate control 
In a microarray statistical analysis, controlling the false discovery rate is one of the most important 
steps before the selection of the differentially expressed genes. A microarray data analysis involves 
simultaneous hypothesis testing of several thousands to tens of thousands of genes and the 
probability of finding a false positive increase when the number of genes tested increases. To 
correct for this multiple hypothesis testing problems and generate less false positives, a false 
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discovery rate usually known as the rate of ‘type I errors’ must be corrected. (Reiner et al., 2003) 
The most popular form of adjustment is introduced by Benjamini and Hochberg that controls the 
false discovery rate. R’s base statistical packages provide p-value adjustment functions to control 
the false positives. There are several options such as Bonferroni adjustment and FDR (known as 
Benjamini Hochberg adjustment in R) adjustment, and FDR method tends to be most powerful as 
the false discovery rate is a less stringent condition than family-wise error rate. (Benjamini & 
Hochberg, 1995) Usually the p-values obtained from the moderated t-statistics after adjustment 
for multiple testing are used to select differentially expressed genes along with other criteria such 
as the log fold change values. Following the p-value adjustment, a p-value threshold is selected 
for identification of differentially expressed genes. If for example, p-value threshold of 0.05 has 
been selected, all the genes with p-values below 0.05 are selected, meaning that the expected 
proportion of false discoveries in the selected group should be less than 5%. (Reiner et al., 2003) 
Researchers can set p-values based on how strictly they want to control the false positives but in a 
typical biomedical researches p-value threshold is usually set at 0.05. (Dalman, Deeter, 
Nimishakavi, & Duan, 2012) By controlling the false discovery rate, a more reliable set of genes 
from differential expression analysis can be selected for subsequent clustering or functional 
analysis. 
 
2.3.3.3 Clustering and visualization techniques 
Clustering of gene expression data usually falls into class discovery problem. In class discovery, 
genes that are similarly expressed are grouped together using several clustering methods and the 
results are correlated to biology for interpretations. If the genes are co-regulated and expressed (up 
or down regulation) simultaneously, they may be functional related genes and the functionally 
related genes can be clustered into groups. Clustering, like principal component analysis can 
reduce the dimensionality of microarray data. (Wang et al., 2009) Clustering can be applied to 
both genes and experimental samples and when the experimental samples (usually columns from 
the matrix) are clustered for instance, the drugs with similar effects can be identified. Hierarchical 
clustering technique has been most popular clustering method to identify a partition of the 
experimental samples more than the genes as the size of samples are less than the size of genes 
and it is usually difficult to interpret the dendrogram produced by the gene clustering. (Wang et 
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al., 2009) In hierarchical clustering, each cluster are divided into smaller clusters that look like a 
tree structure called dendrogram. In agglomerative hierarchical clustering, the single-gene clusters 
are joined by the closest clusters until all the genes have been joined into the original cluster of 
genes. There are several inter-cluster distance approaches used by hierarchical clustering including, 
single linkage, complete linkage, average linkage and centroid linkage. (D'haeseleer, 2005) Once 
the genes have been hierarchically clustered using some linkage methods, their expression patterns 
are displayed using visualization tools. Heatmaps are very useful visualization tool to monitor gene 
expression pattern overall. Heatmaps consist of rectangular array of coloured blocks that represent 
the expression level of genes. Typically, red maps represent up-regulation and green maps 
represent down-regulation expression, but many other colour choices can be used too. Through 
heatmaps, the gene expression intensities can be visualized to examine how strongly has the gene 
been expressed under different experimental conditions and identify similarly expressed group of 
genes. (Wang et al., 2009) 
 
2.3.3.3.1 Weighted gene co-expression network analysis 
In bioinformatics applications, co-expression analysis is a powerful tool to identify genes involved 
in the same biological process. Genes that display similar expression patterns are likely to be 
involved in same biological functions or pathways and these genes are known as co-expressed 
genes. Co-expressed genes are useful in identifying candidate genes for metabolic pathway 
enzymes or transcription factors that regulate them. (Oldham et al., 2008) Bioconductor offers a 
comprehensive software package for performing various aspects of weighted gene correlation 
network analysis known as Weighted Gene Co-expression Network Analysis (WGCNA). 
(Langfelder & Horvath, 2008) WGCNA package provides several functions to perform weighted 
correlation network analysis, module detection, gene selection, visualization and interfacing with 
external software such as ‘Cytoscape’ (Shannon et al., 2003). Typically, WGCNA aims to identify 
modules (clusters) of highly correlated genes that have high topological overlap which is a pair-
wise measure that displays two genes’ co-expression relationships with other genes. (Oldham et 
al., 2008) High topological overlap displayed by the genes show that they are highly correlated in 
the network. WGCNA uses hierarchical average linkage clustering method to cluster highly 
correlated genes into a co-expression module. (Langfelder & Horvath, 2008) The figure 2.6 















Figure 2.6 Schematic overview of WGCNA procedures. A gene co-expression networks are 
constructed to identify modules of co-expressed genes using hierarchical average linkage clustering 
method and dynamic tree cut. Significant modules can be selected, and they can be related to their 
biological traits information. A subsequent functional enrichment analysis can be performed using 
the gene modules (Langfelder & Horvath, 2008). 
 
Once different co-expression modules are identified using WGCNA, a gene ontology enrichment 
analysis or biological pathway analysis can be performed to identify biological functions or 
pathways that are significantly enriched by the co-expression modules as seen in the last step of 
figure 2.6. WGCNA approach has been widely used in different cancer and brain researches 





2.4 Biological interpretations 
The usual goal of microarray experiments is to identify a set of differentially expressed genes 
between two or more conditions. (Sánchez & de Villa, 2008) Typically, the analysis will produce 
a long list of genes that had passed several criteria such as p-value threshold and the log fold-
change. These genes are known to be statistically significant and the researchers can associate 
these genes to a specific biological functions or pathways that the genes are involved in. There are 
databases designed for this purpose namely, Gene Ontology (GO) and Kyoto Encyclopaedia of 
Genes and Genomes (KEGG).  
The gene enrichment analysis is a high-throughput approach that is used to associate the list of 
identified genes to their biological functions or processes and the pathways using databases such 
as GO and KEGG. (Huang, Sherman, & Lempicki, 2008) The gene set enrichment analysis is 
usually performed to identify if the differentially expressed genes have been significantly enriched 
or impoverished in a given category of biological processes. During the analysis, a numerical 
variable such as p-values are used to rank the enrichment score based on the presence or absence 
of the genes in the specific biological processes. A Kolmogorov-Smirnov test is usually used to 
make decisions about the list of genes’ representations in the biological process. (Sánchez & de 
Villa, 2008)  
There are several high-throughput enrichment analysis tools developed such as Onto-Express, 
GoMiner, EASE and DAVID. The GO enrichment analysis can also be done through the WGCNA 
package which is a co-expression analysis package available from the Bioconductor Project 
(section 2.3.2.1). (Huang et al., 2008) The tools available for enrichment analysis may have 
different functionalities and features but the underlying concept of the tools is the same. The figure 




















Figure 2.7 The schematic overview of the infrastructure of gene enrichment analysis tools. There are 
three major layers to this workflow. In the first layer (backend annotation database), annotation 
databases such as GO and KEGG are available. In the second layer (data mining), the user inputs 
the list of genes and goes through several statistical tests to generate results such as enrichment score 
using p-values. Each layer has a great influence in the result (Huang et al., 2008). 
 
Due to the complex nature of biological data-mining, the enrichment analysis of a large list of 
differentially expressed genes is still regarded as an exploratory data analysis than a pure statistical 
analysis. (Huang et al., 2008) Typically, the best biological conclusions can be drawn, when the 
researcher’s thorough knowledge of biology, integration of useful biological databases and 
incorporation of computing algorithms and statistical methodologies are combined. The 
enrichment analysis tools must still be improved, and it is crucial that the researchers must take 
into consideration of the biological facts and statistical analysis results together to interpret the 




2.5 Challenges with microarrays  
Microarray technology has been very useful in drug discovery and disease researches, but data 
mining with microarray still presents several challenges. The sample size in microarray analysis is 
usually small and this may be problematic. The number of genes may range from 1,000s to 10,000s 
while the size of samples ranges from 10s to 100s only. The number of samples in microarray 
analysis due to difficulty in the collection of microarray samples, could significantly increase the 
finding of false positives that are due to chances and not biological variation. (Piatetsky-Shapiro 
& Tamayo, 2003) The amount and quality of RNA isolated from microarray experiments remains 
a major challenge, due to the complex nature of tissue samples obtained. This limitation has created 
false microarray data that were generated from degraded mRNA sources and the experiments had 
to be replicated several times to eliminate errors. (Russo, Zegar, & Giordano, 2003) Currently, 
microarray technology is limited by the tissue samples, arrays and analysis methodologies. Due to 
these reasons, microarray data analysis pipeline requires more robust and validated models to 
accurately analyse noisy microarray data. 
 
2.6 RNA-Seq 
RNA-Seq is a recent gene expression profiling method that uses deep-sequencing technologies. 
There are several advantages of using RNA-Seq profiling method over existing methods, although, 
it is still under an active development. (Mortazavi, Williams, McCue, Schaeffer, & Wold, 2008) 
RNA-Seq technology can be useful in expression profiling of non-model organisms with genome 
sequences that have not yet been determined, whereas existing hybridization-based arrays are 
limited to existing genome sequences. It is also possible to precisely identify location of 
transcription boundaries to a single-base resolution. (Sánchez & de Villa, 2008) RNA-Seq 
typically also has very low background signal with a large dynamic range of expression levels for 
transcript detection. RNA-Seq also provide an accurate quantification of expression levels. 
(Sánchez & de Villa, 2008) As with any other array technologies, RNA-Seq also has limitations 
of efficiently storing, retrieving and processing of large quantities of expression data, but in overall 
RNA-Seq offers far more accurate and precise quantification of transcriptional expression 
measurements compared to classical hybridized-based arrays like microarrays. The expression 
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profiling technology must be carefully chosen by the researcher accordingly, to match the purpose 
of the research as each technology has its own advantages and disadvantages. 
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3 GLYCOBIOLOGY AND GLYCOSYLTRANSFERASES 
 
3.1 Introduction to glycobiology 
Glycobiology by its definition is the study of the structure, chemistry, biosynthesis and biological 
functions of glycans known as carbohydrates and their derivatives.  Glycobiology is a small but 
fast-growing field in biology with its relevance in biomedicine, biotechnology and cancer 
researches. Proteomics, which is the study of protein expression, modifications, structures and 
functions has expanded our knowledge of proteins but typically in eukaryotic cells, proteins 
undergo posttranslational modifications. One of the major posttranslational modifications is 
glycosylation whereby glycans essential for cell’s viability are attached to the protein structures. 
Oligosaccharides can be covalently attached to proteins in two ways namely, N-glycosidic linkage 
between N-Acetylglucosamine (GlcNAc) and an asparagine residue or an O-glycosidic linkage 
between N-Acetylglucosamine (GalNAc) and the hydroxyl group of serine or threonine. (Stanley, 
Schachter, & Taniguchi, 2009) There are many functions of glycans in cell but one of its main 
functions is to be involved in intercellular interactions where cell to cell and cell to pathogen 
contact occurs through glycan-protein interactions. Glycan to protein interactions occur through 
glycosylation which is modulated by glycosyltransferase enzymes. There are currently more than 
150 different glycosyltransferase enzymes identified but there are at least double this number to 
be characterized. In this short chapter, an overview of carbohydrates, glycosylation and 
glycosyltransferase will be presented and their roles in breast cancer will be discussed to give an 
idea of how the applications of glycobiology can be useful in cancer researches and the 
development of potential cancer biomarkers. 
 
3.1.1 Carbohydrates 
There are two major classes of molecules required to build a cell, namely, lipids and carbohydrates. 
Carbohydrates are biomolecules that are involved in numerous biological processes including, 
oligomerization, protein folding, cell to cell recognition and response and host-pathogen 
interactions. (Berninsone, 2005) Carbohydrates function as an intermediate in energy generation 
and signalling effectors, structural components and recognition markers and major 
posttranslational modifications of proteins are also encompassed by carbohydrates (Stanley et al., 
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2009) With this, it is apparent how a small number of carbohydrate related genes can create 
complexities in development, growth and functioning of a cell in a biological system. 
 
3.1.1.1 Monosaccharides 
Monosaccharides, which are the basic units of carbohydrates are the basic structural units of 
glycans which is a compound consisting of large number of monosaccharides that are linked via 
glycosidic linkages. Monosaccharides cannot be hydrolysed into a simpler form and there are two 
types of monosaccharides according to the position of carbonyl group in the carbon chain. If the 
carbonyl is attached at the end of carbon chain, they are called aldose of if it is attached to the inner 
carbon, it is called ketose (Stanley et al., 2009). In its natural state, a monosaccharide exists in 







Figure 3.1 Open chain and ring formation of glucose. Typically, changes in the orientation of 
hydroxyl groups around specific carbon atoms create a new molecule such as galactose that is the C-
4 epimer of glucose (Stanley et al., 2009).  
 
Monosaccharides can be attached to another residue via a glycosidic linkage that involves the 
hydroxyl group of anomeric centres, creating α linkages or β linkages. The two different linkages 
confer different biological functions of glycans. (Berninsone, 2005) A glycoconjugates are a 
compound that consists of more than one monosaccharides or oligosaccharide units that are 
covalently bonded to a non-carbohydrate moiety and usually, the glycans constitute a major 
portion of glycoconjugates. There are several hundred distinct monosaccharides occurring 
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naturally but only a few of these are found in animal glycans. The table 3.1 shows the list of 
common monosaccharide units of glycoconjugates. 
Table 3.1 List of most common monosaccharides units of glycoconjugates. 
Name No. of Carbons Description 
Pentose 5 Neutral sugars, e.g. D-xylose 
Hexose 6 Neutral sugars, e.g. D-glucose (Glc), D-galactose (Gal), 
D-mannose (Man) 
Hexosamines 6 Hexoses with amino groups at the 2-position, e.g. N-
acetyl-D-glucosamine (GlcNac) and N-acetyl-D-
galactosamine (GalNac) 
Deoxyhexoses 6 Neutral sugar without the hydroxyl group at the 6-position 
Uronic Acids 6 Hexose with a negatively charged carboxylate at the 6-
position, e.g. D-glucuronic acid (GlcA) 
Sialic Acids 9 N-acetylneuraminic acid (Neu5Ac) 
 
This limited set of monosaccharides can undergo several different modifications, and this increases 
their diversity and mediates their biological functions. The hydroxyl groups of monosaccharides 
thus undergo modifications such as, phosphorylation, methylation, O-acetylation, or fatty 
acylation. (Stanley et al., 2009) 
 
3.1.1.2 Classes of glycoconjugates and glycans 
The classes of glycans naturally occurring are defined by the type of linkage to the protein or lipids. 
Proteins can also have glycoconjugates covalently attached via N or O linkages. (Pinho & Reis, 
2015) N-glycans are oligosaccharides chain that has asparagine residue covalently attached to a 
polypeptide chain. An O-glycans have a linkage between sugar chain and polypeptide via N-
acetylgalactosamine (GalNac) to a hydroxyl group of a serine or threonine residue. Mucin is a 
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glycoprotein that has many O-glycans that are grouped together. (Stanley et al., 2009) Figure 3.2 













Figure 3.2 Different classes of common glycoconjugates occurring in mammalian cells. 
Glycosphingolipids typically appear on the outer leaflet of the cell plasma membrane. These glycans 
can be modified by terminal sialic acids. Saccharides can be covalently attached to a polypeptide 
backbone via N-linkage to Asn or O-linkage to Ser/Thr to produce a glycoprotein (Iha & Yamada, 
2013). 
 
There are other major glycoconjugates including the proteoglycans and glycosphingolipids (figure 
3.2). Proteoglycans usually have glycosaminoglycan (GAG) such as keratan sulphate in its 
component. Glycosphingolipids are composed of glycans that are linked to a lipid ceramide and 
these molecules have a series of neutral structures and gangliosides that carries sialic acids which 
is known to regulate the receptor tyrosine kinase (RTK) signalling. (Pinho & Reis, 2015) (Iha & 
Yamada, 2013) Glycan chain structures unlike protein sequences are not determined and 
characterized directly by the genome and these are the secondary gene product. A few number of 
genes in the human genome encode for enzymes and transporters directly involved in the 
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biosynthesis and assembly of glycans through posttranslational modifications of proteins and 
glycosylation by enzymatic processes. (Stanley et al., 2009) This results in glycans having many 
different combinatorial ways they can assemble and for this reason, it is not possible to understand 
all the structures and pathways to predict the structures of glycans in a given cell. (Stanley et al., 
2009) Additionally, environmental changes can result in significant changes of glycan structures 
and it is the complex and dynamic nature of glycosylation that makes the research field of 
glycobiology more difficult to conduct than any other topics such as nucleic acids or proteins. 
 
3.1.2 Glycosylation 
Glycosylation is a biological reaction or enzymatic process that attaches carbohydrates to proteins, 
lipids and other organic molecules. (Kailemia, Park, & Lebrilla, 2017) Glycosylation is the most 
common form of posttranslational modification and in this reaction, generally, saccharide units are 
covalently attached to the target proteins and sequential elongation of the branches proceed. 
(Hakomori, 2002) Glycosylation is typically proceeded by numerous glycan modifying enzymes 
including, glycosyltransferases and glycosidases resulting in various complex carbohydrates like, 
glycoproteins, glycolipids and proteoglycans. The rate of glycosylation for a given protein is 
determined by the presence and the frequency of glycosylation sites of proteins as well as the 
transcriptional levels and activities of glycosylation enzymes within the cell. (Pinho & Reis, 2015) 
(Munkley & Elliott, 2016) 
The glycosylation in a cell produce two types of glycans namely, N-glycans and O-glycans (section 
3.1.1.2) In N-glycosylation, an oligosaccharide precursor is transferred in groups to nascent 
proteins in the endoplasmic reticulum (ER). (Li, Song, & Qin, 2010) A subsequent reaction happen 
in the ER after the transfer of precursor that includes glucose removal and addition in a cycle that 
contributes to the protein folding. Additionally, N-glycan chains can be even more diversified in 
the Golgi apparatus. (Reis, Osorio, Silva, Gomes, & David, 2010) O-glycosylation is the process 
where glycans get O-linked to a serine or a threonine residue (figure 3.2), and the rate of this type 
of glycosylation in glycoproteins is high on a membrane-bound mucin. In O-linked glycosylation, 
N-acetylglucosamine (GalNAc), is transferred to serine and threonine residues from a sugar donor 
UDP-GalNAc, and this is usually modulated by UDP-GalNAc-polypeptide N-
acetylgalactosaminyl-transferases (ppGalNAc-Ts). Altered transcriptional levels of ppGalNAc-Ts 
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may result in mucin O-glycosylation changes that is present during the malignant transformation 
in a cell. (Reis et al., 2010) In the next section, the enzyme involved in typical glycosylation 
processes will be discussed such as glycosyltransferase enzymes in terms of its types and roles in 
general. 
3.1.3 Glycosyltransferases  
The glycan biosynthesis is primarily regulated by the glycosyltransferase enzymes that catalyses 
the formation of glycosidic linkage to create carbohydrates, glycoside, oligosaccharides or 
polysaccharides. These enzymes assemble monosaccharides moieties of simple nucleotide sugar 
donor substrate (UDP-Gal, GDP-Fuc or CMP-Sia) into linear and branched glycan chains by 
transferring glycosyl residues from nucleotide-activated phosphoglycosides to other carbohydrates. 




Figure 3.3 Glycosylation reaction showing activity of glycosyltransferase enzyme. A glycosyl donors 
include nucleotide sugar and dolichol-phosphate-linked monosaccharides and oligosaccharides and 
an acceptor substrate includes either oligosaccharides or proteins and ceramide for glycoproteins 
(Stanley et al., 2009). 
 
During glycosylation, glycosyltransferase enzymes use acceptor substrates such as 
oligosaccharides, monosaccharides, polypeptides, lipids and other organic molecules to initiate the 
synthesis of glycoconjugates. (Pinho & Reis, 2015) (Stanley et al., 2009) The glycosyltransferase 
enzymes act sequentially to produce acceptor substrates that will be used in other subsequent 
reactions and these enzymes primarily plays role in the elongation of glycan chains that results in 
a linear or a branched polymer that has monosaccharides linked to one another. (Stanley et al., 
2009) There are glycosidases that are involved also in the biosynthesis of glycans. These enzymes 
generate intermediates that can be acted by glycosyltransferase by removing monosaccharides and 
this is relevant process especially in the formation of N-glycans. For instance, glycosidases along 
with mannosidases can sequentially trim the nascent glycoprotein glycan so that 
glycosyltransferases can modify them to form a more complex and hybrid-type chains. There are 
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several glycan-modifying enzymes that utilizes variety of different donors such as 
sulfotransferases, phosphotransferases, O-acetyl-transferases and O-methyltransferases. (Stanley 
et al., 2009) (Paulson & Colley, 1989) Overall, a clear understanding of functional roles of 
glycosyltransferase is required to better understand how and what altered glycan changes could 
result in development and progression of cancer states. 
 
3.2 Glycobiology in cancer 
Glycobiology has recently gained an increased attention in cancer researches to understand the 
mechanisms of cancer and set up and develop therapeutic strategies and diagnostics. Glycosylation 
as described in section 3.1.2, is a common form of posttranslational modification (PTM) and this 
process plays an important role as a regulatory mechanism controlling various physio-pathological 
processes in a cell. (Pinho & Reis, 2015) Different types of glycoconjugates generated through 
glycosylation in a cell plays roles in cancer cell processes as well as the tumour microenvironment 
that leads to cancer progression. The compositional changes of glycans that have been added to 
either glycoproteins or glycolipids can aid various stages of cancer progression and this has been 
illustrated in figure 3.4. (Hakomori, 2002) (Munkley & Elliott, 2016) The biochemical 
mechanisms of altered glycan production remain poorly understood and it is predicted that the 
alteration of glycan structures occurs due to several reasons including, genetic mutations, changes 























Figure 3.4 Glycosylation processes in carcinogenesis. Six important steps involved in the metastasis 
of carcinoma cells are illustrated. Initially, N-glycosylation influences the growth receptor and the 
concentration of growth factors increases. The N-linked glycosylation mediates cell to cell adhesion 
and O-glycosylated mucins act on a specific leukocyte and initiates immune system response targeting 
the malignant cells. The integrin functionalities are regulated by N-linked glycosylation to enhance 
motility of transformed cells. Finally, via binding of Lewis antigens by endothelial selectins, 
endothelium adhesion is mediated (Potapenko et al., 2010).  
 
The altered glycosylation is closely linked to the progression of cancer in several ways (figure 3.4). 
The glycosylation change affects and modifies the cell surface carbohydrate structures that play 
significant roles in cell to cell interaction, signalling and adhesion properties that are essential for 
a tumour cell metastasis along with tumour cell interaction with the immune system. (Potapenko 
et al., 2010) Typically, malignancy introduced due to aberrant changes in glycosylation results in 
the creation of novel structures, precursor accumulation, persistence of truncated structures and a 
decreased expression of certain structures in a cell. (Hakomori, 2002) 
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 Through aberrant glycosylation, the molecular heterogeneity and functional diversity can be 
introduced. Aberrant glycosylation is protein specific, site specific and cell specific and this 
specificity of glycosylation process is largely dependent on factors such as incomplete synthesis 
and neo-synthesis processes. The incomplete synthesis process usually occurs in early stages of 
cancer and this process involves biosynthesis of truncated structures due to malfunctioning of 
normal complex glycan synthesis process in the epithelial cells. In contrast, neo-synthesis 
processes are frequent in advanced stages of cancer whereby cancer associated genes are induced 
and they are involved in the direct expression of carbohydrates. (Pinho & Reis, 2015) It has been 
seen that aberrant glycosylation that leads to altered glycan structures in cancer cells can be 
attributed to dynamic expression changes of glycosyltransferase at the transcriptional level, tertiary 
conformation of the peptide backbone and localization of appropriate glycosyltransferases in the 
Golgi apparatus. (Pinho & Reis, 2015) (Reis et al., 2010) 
With a reference to breast cancer, the changes in PTM of proteins that occur during neoplastic 
transformation affects breast cancer and with this, an understanding of PTM changes that 
contribute to oncogenic cancer progression would significantly aid the development of anticancer 
agents that prevents these PTM. (Krueger & Srivastava, 2006) There are four main glycan groups 
that are involved in target attachment namely, N-linked glycans, O-linked glycans, 
glycosaminoglycans (GAGs) and polysaccharides. (Potapenko et al., 2010) The N-linked, O-
linked glycans and GAGs are attached to the polypeptide chains. The glycosphingolipids from 
GAGs form most glycolipids in a cell. The N-glycans are involved in growth, differentiation, 
adhesion and metastasis which is important for tumour cell progression. The O-glycans are 
involved in adhesion and immune response modulation. (Pinho & Reis, 2015) (Meany & Chan, 
2011) 
Sialylation and fucosylation are one of the most widely occurring cancer related glycosylation 
changes along with N- and O-linked glycan branching. The α2,6- and α2,3-linked sialylation has 
been identified to be most closely associated with cancer, involved in various cellular functions 
like cell recognition, adhesion and signalling. This process is typically catalysed by ST3Gal-I, 
sialyltransferase enzymes. There are several subgroups of sialyltransferase enzymes and these are 
type II transmembrane glycoproteins with a short amino (NH2) cytoplasmic tail that resides in the 
lumen of Golgi. (Pinho & Reis, 2015) (Brockhausen, 2006) Fucosylated glycans can be 
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synthesized by fucosyltransferases (encoded by FUT). In fucosylation, α1,6-fucouse is added to 
the GlcNAc residue of N-glycans catalysed by FUT8 enzyme and overexpression of this type of 
enzyme typically influences breast cancer. The increase in dimerization and phosphorylation in 
breast cancer due to increased fucosylation can result in the increase of epidermal growth factor 
receptor (EGFR) mediated signalling and this plays a significant role in tumour cell growth and 
development of malignancy. (Pinho & Reis, 2015) (Kölbl, Andergassen, & Jeschke, 2015) 
The glycosyltransferases (section 3.1.3) have been used to characterize glycosylation pathways 
and the understanding of the roles of glycosyltransferases in glycosylation enzymatic processes 
and a thorough study of glycosyltransferase expression at the transcriptional level therefore, have 
become a critical step to developing a biomarker and anticancer agents for diseases like breast 
cancer. Additionally, an increasing amount of glycomics, glycoproteomics and transcriptomics 
data will provide an exciting opportunity to discovery of novel targets and strategies for the 
diagnosis and treatment of diseases like breast cancer. In the next chapter, the breast cancer gene 
expression dataset and its pre-processing procedures followed for this project will be discussed. 
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4 GENE EXPRESSION DATA 
 
4.1 Gene expression data overview 
The microarray gene expression dataset used in this work was retrieved from the CMap website 
(available at: http://www.broadinstitute.org/cmap/). In this dataset, gene expression was measured 
in the MCF-7 human breast cancer cell line, in two types of samples. The first samples were treated 
with several FDA-approved compounds, and the second type were untreated control samples. The 
dataset was loaded in RStudio, a statistical programming development environment, and several 
indispensable cleaning and pre-processing steps were followed before constructing a complete 
numerical gene expression matrix for subsequent analyses. The complete gene expression matrix 
was annotated using necessary annotation libraries and finally, the known GT gene list was 
matched against annotated genes to construct separate expression matrices with GT genes. The 
expression matrices were constructed and formatted to perform differential gene expression 
analysis and WGCNA. 
 
4.2 The Connectivity Map 
The advancement of human genome sequencing technologies, such as NGS techniques, has led to 
an explosion of new insights into the genetic basis of disease. Through sequencing analysis, 
disease-associated genes are identifiable, but their cellular functions remain unclear. From the 
chemical biology and drug discovery perspectives, new drugs were designed and developed with 
the use of advanced screening methodologies. This has led to the systemic establishment of 
chemical libraries and clinical therapeutics have entered the pharmaceutical markets (Lamb et al., 
2006). However, it remains unclear what methods must be deployed to systematically determine 
the cellular effects of these novel therapeutics to potentially reduce side effects that limit clinical 
use. 
The CMap project was initiated in 2006 at the Broad Institute, a biomedical and genomic research 
centre located in Cambridge, Massachusetts, USA, by (Lamb et al.,  2006).  Lamb et al. (2006) 
have hypothesized that the creation of a comprehensive genome-scale library of cellular signatures 
that catalogues transcriptional responses to chemical, genetic, and disease-related perturbations 
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would potentially solve the above-mentioned issues. It is predicted that previously unknown 
connections between several proteins, or between compounds with similar functions but different 
structures, could be unveiled through the examination of gene signatures with high similarity. 
Ultimately, the CMap project aimed to establish systemic relations among diseases, physiological 
processes, and the action of therapeutic molecules. This has led to the creation of a large public 
database of genome-wide transcriptional expression data with pattern-matching tools to detect 
similarities among gene signatures. Lamb et al. have named this tool the Connectivity Map (Lamb 
et al., 2006). The CMap has a web interface that could serve as a functional look-up table for the 
genome and, in connection with its interface, the database provides actual transcriptional 
expression profiles used to identify their gene signatures (Lamb et al., 2006). It is expected that 
CMap tools could aid researchers in the field of computational biology and chemical biology to 












Figure 4.1 Schematic view of the Connectivity Map (CMap) concept and process. CMap provides a 
comparison method to measure similarities between a set of phenotype gene signatures and reference 
profiles from cell lines treated with FDA-approved compounds, and corresponding controls. The 
rank-ordered pattern-matching algorithm calculates a connectivity score between each pair of gene 





The current version of CMap, which includes L1000 assay data, was released on September 12, 
2017, and is available on the cloud-based CLUE software platform together with online gene 
expression analysis tools (available at: https://clue.io/). The newest library contains over 1.5 
million gene expression profiles from 5,000 therapeutic compounds and 3,000 genetic reagents. 
The earlier Affymetrix microarray-based CMap data (build 02) are publicly available via Gene 
Expression Omnibus (GEO) or can be manually downloaded in batch files from the Broad Institute 
website (available at: https://www.broadinstitute.org/). CMap build 02 was used in this work and 
the dataset contains more than 7,000 gene expression profiles representing 1,309 FDA-approved 
therapeutic compounds measured in five different cell lines. There are many applications of CMap 
datasets and the next section provides a review of the literature relating to these applications. 
 
4.2.1.1 Cell lines 
A cell line is developed from a single cell cultured in a given medium. It contains uniform genetic 
material and is widely used to perform biological studies such as drug metabolism testing, 
cytotoxicity, and gene function analyses. A usual caveat when using cell lines to perform 
biological research is that one must not have blind faith in the output derived from cell lines, as 
these may not always replicate primary cells accurately. However, cell lines have several 
advantages when performing scientific studies, such as cost-effectiveness and convenience (Lee, 
Kuo, Whitmore, & Sklar, 2000). Lamb et al. generated transcriptional expression profiles based 
on four different cell lines: these are listed in table 4.1, along with the number of experiments 
performed and the number of different drugs used to treat the respective cell lines (Lamb et al., 
2006). 
Table 4.1 Cell lines used in the Connectivity Map database 
Cell line Type Experiments No. of drugs used 
MCF-7 Breast cancer  3095 1294 
PC3 Prostate cancer  1741 1182 
HL60 Leukaemia cell 1229 1078 
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SKMEL5 Melanoma 17 17 
 
Lamb et al. generated most of their data in the MCF-7 breast cancer epithelial cell line as it is by 
far the most standard reference cell line in laboratories around the world and has been molecularly 
characterized most extensively (Lamb et al., 2006). 
 
4.2.1.2 Perturbagens 
Perturbagens are biological substances that disrupt intracellular processes. The very first CMap 
database (build 01) studied the effects of 164 distinct small molecule perturbagens on different 
cell lines (Lamb, 2007). For the work presented here, the CMap build 02 database was used. 
According to Lamb et al., the perturbagens used in their work range from FDA-approved drugs to 
non-drug bioactive compounds (Lamb et al., 2006). To identify any compounds sharing a 
molecular signature, compounds with shared targets were considered. Compounds with the same 
clinical indications were included in this profiling to infer connections between therapeutic classes, 
although the compounds’ chemical structures and molecular mechanisms of action were different. 
A detailed description of specific compounds used in this research work is presented in the section 
4.4. 
 
4.2.1.3 Concentration and duration of treatment 
Lamb et al. performed expression profiling using a range of treatment concentrations, including 
concentrations that were reported to be effective in different cell lines, to explore the effect of 
treatment dose in expression profiling (Lamb et al., 2006). The duration of treatment was uniform 
across all compounds. Expression levels were measured 6 h after the addition of compounds as the 
goal was to observe gene signatures related to direct mechanisms of action. For this research work, 




4.2.1.4 Gene expression profiling methods  
The following section describes how Lamb et al. generated their gene expression profiles (Lamb 
et al., 2006). This collection of gene expression profiles from different treatment and control 
samples forms the CMap database. Expression profiling was done in batches of either 6-well dishes 
(known as the development batch) with four compound treatments and one corresponding control, 
or 96-well dishes (known as the production batch) with 42 compound treatments and six controls. 
Cells were treated 24 h after plating. Full details of the CMap drug treatment dataset (build 02) are 
available at http://www.broad.mit.edu/cmap as “cmap_instance.txt”. 
TRIzol (Invitrogen) was used to isolate total RNA. Total isolated RNA samples were hybridized 
to microarray for complementary RNA (cRNA) synthesis, and scanning was done using 
Affymetrix GeneChip products. Total RNA extracted from development batches was processed 
using the HG-U133A array, while total RNA from production batches was processed using the 
HT_HG-U133A array. An HT scanner from Affymetrix (supporting information available at: 
https://www.affymetrix.com) was used to scan high-throughput arrays (HTA) and produce image 
files that contain numerical expression levels across genes. Faulty scans that did not meet the 
required basic data quality were discarded (Lamb, 2007). The dataset is available online in the 
CMap database (http://www.broad.mit.edu/cmap). 
 
4.3 Applications of CMap 
Since the advent of transcriptional gene expression profiling methods, many successful and radical 
biomedical science discoveries have been made. Using this technology, Lamb et al. initiated the 
CMap project, and its tools have successfully provided data-driven and systemic approaches to 
unveiling connections between genes, chemicals, and biological conditions such as diseases (Lamb 
et al., 2006). Since its introduction in 2006, many applications of CMap have shown promising 
results. The CMap tools and the database provided by the web interface have especially contributed 
to drug discovery and development, specifically in identifying new indications for existing drugs 
and elucidating the mode of action of novel chemicals (K. Wang et al., 2015). 
Drug repurposing is one of the most popular applications of CMap. Drugs available on the market 
today have more than one effect or side effect, and bioactive compounds are prescribed for several 
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different indications (K. Wang et al., 2015). Pharmaceutical industries are continuously looking to 
reduce the cost, risk, and time-to-market associated with their drug products by employing drug 
repurposing strategies, which aim to identify new indications for existing drugs. 
In addition to drug repurposing, CMap also has applications in lead discovery to identify novel 
active compounds for pharmaceutical pipelines across various disease areas. Traditionally, target-
based drug discovery prioritized identification of putative therapeutic drug targets before 
compound screening. However, CMap has employed a phenotype-based approach that does not 
require a deep understanding of cellular regulatory networks and regulatory module functions. 
Researchers could simply query CMap using the gene signature of a diseased tissue sample to 
identify therapeutic molecules that could modulate this disease state (K. Wang et al., 2015). The 
use of CMap in drug repurposing and lead discovery has yielded significant results and it is 
expected that the use of established tools such as CMap for drug research will continue to increase.  
In the next few paragraphs, the impressive applications of CMap in drug repurposing, along with 
several other applications including lead discovery, will be discussed. 
 
4.3.1 Drug repurposing via machine learning 
Napolitano et al. developed a machine learning computational tool to predict drug repurposing 
(Napolitano et al., 2013). According to their studies, many traditional computational approaches 
to drug repurposing focused only on changes in transcriptional expression levels in response to 
drug treatment, or on drug-disease relationships. Specifically, correlations between drug-
associated and disease-associated expression signatures were examined. Although this type of 
approach was able to identify and validate some novel therapeutic indications, the noisy and 
complex nature of gene expression data and the limited availability of genomic data for many 
diseases slowed down drug repurposing studies. For instance, publicly available gene expression 
data were generated from patients that had already been treated with other drugs and merging 
several information levels together makes the drug repurposing process less reliable and robust. 
To overcome these constraints, the authors focused on enhancing the predictability of existing 
computational tools with machine learning classification algorithms by incorporating drug 
characteristics and not considering data concerning the disease (Napolitano et al., 2013). In this 
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way, they were able to present mismatches between known and predicted drug classification. The 
mismatches were interpreted as potential alternative therapeutic indications.  
The traditional supervised machine learning classification algorithm Support Vector Machine 
(SVM) was used to build the classifier. The authors predicted drug repurposing based on the 
similarity of chemical structures, the proximity of their targets within the protein-protein 
interaction network, and finally, gene expression correlation patterns after treatment with drugs. 
The gene expression profiles used to train the machine learning classifier were derived from the 
CMap database (Napolitano et al., 2013).  
The classifier achieved an accuracy of 78% and based on this, the authors re-interpreted the top 
misclassifications as re-classifications after several statistical procedures (Napolitano et al., 2013). 
The approach followed by this study maximized re-classification efficacy towards the repurposing 
of known drugs and novel drug discovery (Napolitano et al., 2013). The following flowchart 











Figure 4.2 Flowchart of the machine learning classifier development process followed by Wang et al. 





4.3.2 Drug functional similarity analysis 
Cha et al. aimed to identify the functional similarity of different drugs by comparing the 
transcriptional profiles of CMap samples in response to drug treatment (Cha, Kim, Oh, Shin, & Yi, 
2014). CMap data are especially useful in unveiling the unknown characteristics of small 
compounds if multiple features are considered. The authors diversified features of comparison in 
gene expression by combining signatures of differentially expressed genes (DEGs) and 
differentially co-expressed modules (DCMs), and this integration provided more robust and 
accurate methods of searching for similar drugs based on expression profiles (Cha et al., 2014). 
Co-expressed gene modules, in addition to DEGs, can be very useful features, and several studies 
have identified certain DCMs involved in cancer development, even though differences in 
expression levels were small (Lai, Wu, Chen, & Zhao, 2004; Carter, Brechbühler, Griffin, & Bond, 
2004; Kostka & Spang, 2004).  
Cha et al. modified the original linear modelling test that employs a t-test to normalise different 
experimental samples. Significant DCMs were identified using maximal cliques among the co-
expressed modules. Similarity search methods were evaluated by producing a receiver operating 
characteristics (ROC) curve, and an overall performance score of 0.99 was calculated by 
measuring the area under the curve (AUC). Additionally, the authors constructed a drug-drug 
network using similarity search methods to identify drugs having similar gene expression 
responses. In this way, similarity search methods could provide insights into drug repurposing 
using CMap expression profiles. The biggest limitation of this study was the small number of drug 
response samples, as the robust and reliable identification of DCMs requires sufficient sample size. 


















Figure 4.3 Overall procedures adopted by Cha et al. to derive their similarity search methodology 
(Cha et al., 2014). Differentially co-expressed gene module (DCM) signatures and differentially 
expressed gene (DEG) signatures were identified, and combined scores for the two different 
signatures were calculated by considering the false discovery rate (FDR). 
 
4.3.3 Drug safety evaluation 
Recently, the popularity of using CMap in drug repurposing research has increased, but much less 
attention is given to the potential use of CMap in evaluating drug safety and side effects. Adverse 
drug reactions (ADRs), also known as side effects, are important factors that pharmaceutical 
industries consider when developing new drugs. Wang et al. recently developed a drug safety 
evaluation method using the CMap database to eliminate any potential risks of drugs in the 
preclinical stage of development (Ashburn & Thor, 2004; K. Wang et al., 2015). The authors 
computationally designed a risk score model that predicts drug safety risks based on drug-induced 
gene-gene expression profiles from the CMap database (Ashburn & Thor, 2004). Their results 
showed that the transcriptional expression profiles of drugs that induce ADRs were positively 
correlated with expression profiles in CMap, allowing the authors to effectively identify drugs with 
safety risks. Once again, this study showed how integration of the CMap database and 
computational modelling and analysis can be very useful in the preclinical stage of drug 
development (Ashburn & Thor, 2004). 
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4.3.4 Lead molecule discovery 
Lead molecule discovery is another well-known application of CMap as discussed in section 4.3. 
Wang et al. performed a meta-analysis of two sets of published microarray data (from cancerous 
and non-cancerous samples) to obtain a gene signature with 343 DEGs specific to lung 
adenocarcinoma (G. Wang et al., 2011). The DEGs were submitted to the CMap analysis interface 
to identify drugs that show negative expression correlation with the gene signature obtained in 
their own analysis. The authors identified several compounds that showed negative correlation, 
and selected 17-AAG, an inhibitor of heat shock protein 90 (HSP90), as a lead molecule that 
suppressed growth of lung adenocarcinoma cells in vitro (Kaur & Dufour, 2012). 
In conclusion, the applications of CMap in drug development programs have been highlighted in 
the previous paragraphs. Although CMap has its own limitations, it provides valuable data and 
systematic approaches that can be adopted in drug discovery programs to generate testable 
hypotheses. It is expected that the use of CMap in drug discovery research, including drug 
repurposing and lead molecule discovery, will continue to increase in the future (K. Wang et al., 
2015). 
 
4.4 Data preparation 
This section describes how expression data were initially prepared for this research work. Data 
from gene expression in response to compound treatment were downloaded from the CMap 
database available online. A total number of 7,056 (.CEL) raw expression files were downloaded 
together with the instance (description) file. 
 
4.4.1 Data cleaning 
Data cleaning and filtering form essential part of microarray data analysis in order to select only 
necessary features and discard unnecessary ones. The CMap instance file was loaded in RStudio 
running R version 3.3.3 with necessary data manipulation packages such as “dplyr”, “plyr”, and 
“stringr”. Only treated MCF-7 cell samples were selected for subsequent preparation procedures. 
There were three types of Affymetrix chips used to generate expression profiles, namely HG-
U133A, HT-HG-U133A, and HT_HG-U133_EA. HT_HG-U133A_EA is an early access version 
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of the Affymetrix chip and, due to the small number of samples included, this chip type was 
discarded. In total, 2,911 samples were filtered, of which 2,740 samples were from the HT_HG-
U133A chip and 171 samples from the HG-U133A chip. 
 
4.4.2 Biological replicates and drug information 
Typically, high-throughput microarray experiments for genetic studies are costly and time-
consuming. The production of arrays for experiments can be slow and supply may be limited. Due 
to these reasons, the manufacturers of microarrays sometimes minimize the importance of 
replication in scientific experiments and may underestimate the significance of including 
biological replicates in their studies (Lee et al., 2000). Biological replicates are a set of multiple 
samples of the same tissue measured across multiple treatments. It is expected that these samples 
respond very similarly to treatment. Biological replicates are necessary in microarray data analysis 
as they are used to test variability between samples and confirm that the difference between treated 
samples is truly due to biological variation. There are several advantages to including sufficient 
biological replicates in microarray experiments. First, replicates improve the measurement of 
variation and the statistical significance of tests performed. This is especially important in 
differential gene expression analysis. Second, replicates can be used to detect outliers. Finally, 
precision of gene expression is improved by averaging across replicates (Newton, Kendziorski, 
Richmond, Blattner, & Tsui, 2001).  
In this study, compound-treated samples with at least five biological replicates were selected. 
Control samples (untreated MCF-7 cells) also comprised five biological replicates. In total, 29 
drugs fulfilled this criterion, each with 10 samples: five treated samples and five control samples. 
Five treated samples were randomly selected from each drug to reduce bias by the number of 
experiments. For example, there were 181 replicates treated with Trichostatin A, from which five 
replicates were randomly selected. Finally, all the samples selected were treated with the highest 
drug concentration. 
Information regarding the 29 drugs is available in table 1, appendix B. This information includes 
drug indications, target proteins, and chemical formulae, along with PubChem compound 
identifiers (CIDs). PubChem is a chemical molecule database that contains compound activities in 
biological assays. The system is maintained by the NCBI. PubChem CIDs for each drug have been 
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included in the table. These CIDs can be used to search for more detailed information about the 
compound including its structures, properties, medical information, pharmacology, biochemistry, 
and related literature. 
 
4.5 Data pre-processing 
Data pre-processing is indispensable in microarray data analysis. It is difficult to visually detect 
problems in high-throughput data such as microarray data, as the numerical gene expression 
matrices obtained are huge. This has led to the development of specific microarray data quality 
control procedures (Sánchez & de Villa, 2008). This section describes how the gene expression 
data were quality-controlled, pre-processed, and reformatted for subsequent statistical analyses.  
The treated and control sample gene expression data (.CEL files) from 29 selected drugs were 
loaded in RStudio using necessary Bioconductor packages including the “affy” library. The total 
number of .CEL files loaded in RStudio for each chip type is shown in table 4.3. The shared 
controls were used for this dataset thus, there are more treated samples present in this study.  
Table 4.3 Total number of expression files loaded in RStudio for pre-processing 
Total: 203 HG-U133A chip type HT_HG-U133A chip type 
Treated 14 131 
Control 12 46 
Total 26 177 
 
Several data quality checking procedures and normalizations were performed on the raw gene 





4.5.1 Data quality assessment 
The main goal of data quality assessment is to remove any faults in the data and to determine if 
the data can be considered reliable. This research work utilized assessment tools such as 2D array 
image analysis and density plot analysis. 
 
4.5.1.1 Image quality assessment 
2D images of gene expression array positions can be used for spatial bias diagnostics. These 
images can be used to display spatial trends or biases that cannot be detected in the raw data. The 
raw probe intensity measurement can be used directly to plot images, and data quality can be 
assessed by examining non-random physical factors in the images, including, rings, shadows, lines, 
and strong variation in shade (Gillespie, Lei, Boys, Greenall, & Wilkinson, 2010). 
The loaded gene expression samples for each chip type were used to generate 2D images and the 
























































Figure 4.4 2D image plots of the mismatch and perfect match probe intensities of arrays from each 
chip type HG-U133A and HT_HG-U133A. Control sample arrays are represented by the letter “C”, 
and treated samples are represented by the letter “T”, along with the respective array number. (a) 
First six 2D images from the HG-U133A chip, representing control and treated samples. (b) First six 
2D images from the HT_HG-U133A chip, representing control and treated samples. These samples 
were randomly selected from a total of 203 samples from each chip type. The rest of the sample 2D 
images were analysed separately. 
 
From these 2D images, it is clear that datasets from each chip type did not appear to have any non-
random structures, but maintained pattern consistency, and it can therefore be concluded that 





4.5.1.2 Density plot assessment 
Evaluating density plots of probe intensities is another useful data quality assessment strategy. 
Density plots are generated using log-intensity distribution for each sample array, and the plots are 
super-posed on a single graph for better comparison between arrays. Density plots are especially 
useful as abnormal distributions can easily be detected when the different density plots are super-
posed. For instance, differences in spread and position can be corrected by normalization, although 
significant multi-modality in the density plot distribution including any outlying observations 
could indicate that the data quality is questionable (Gillespie et al., 2010). 
The density plots of log-intensity for all sample arrays from each chip type are shown in figure 4.5. 













Figure 4.5 Density plots of log-intensity (x-axis) distribution of sample arrays from each chip type. 
Both graphs show treated and control samples together. (a) Density plot of 26 samples from the HG-





It is clearly visible from figure 4.5 that there are differences in the spread and positioning of the 
distributions, which can be corrected by normalization. It is also clear that there is no observed 
significant multi-modality in the distributions of density plots for each chip type and it can be 
concluded that CMap data are of high quality. Several data quality assessment tools can 
successfully be used to filter out problematic arrays and control the quality of the data. 
 
4.5.2 Normalization 
Normalization of microarray data must be performed to correct any technical and systemic biases 
caused by factors such as differential dye absorption and spatial heterogeneity in the arrays  
(Sánchez & de Villa, 2008). The next few paragraphs describe several normalization procedures 
performed on the CMap data including RMA and quantile normalization, along with boxplot 
visualization of arrays before and after different normalization steps. 
Boxplot visualization of log-intensity distribution can be very useful to inspect different 
normalization steps and ensure that any technical and systemic biases have been removed from the 
data. Boxplots of samples from each chip type before normalization are shown in figure 4.6. 

































Figure 4.6 Boxplots of sample arrays from each chip type before RMA normalization. (a) HG-U133A 






From the boxplots shown in figure 4.6, it is clear that the spread and position of sample probe 
intensities differ widely. This is due to technical and systemic biases that are introduced during 
microarray experiments and these must be removed to obtain more consistent probe intensities for 
subsequent statistical analyses. 
 
4.5.2.1 RMA normalization 
RMA normalization was designed for data obtained from oligonucleotide chips such as Affymetrix 
gene chips. RMA normalization combines model-based background correction, quantile 
normalization, and robust averaging of samples across hybridization sets at the probe level 
(Gillespie et al., 2010). RMA normalization returns log2-transformed expression values in the 
matrix. Expression matrices from each chip type were RMA-normalized using the “affy” package. 
Boxplots for each chip type obtained after RMA normalization are shown in figure 4.7. Spread 
and position were corrected by RMA normalization and more consistent probe intensities can be 
observed. After RMA normalization of each expression matrix, these can be merged into a single 


































Figure 4.7 Boxplots of sample arrays from each chip type after RMA normalization. (a) HG-U133A 
chip (26 samples). (b) HT_HG-U133A chip (177 samples). More consistent probe intensities across 





4.5.2.2 Quantile normalization 
In many cases, the distribution of expression intensities between different arrays differs when 
arrays are combined, and it is necessary to normalize expression intensities for consistency 
between different arrays to obtain similar distributions (Sánchez & de Villa, 2008, Gillespie et al., 
2010) This can be achieved by quantile normalization. Two different Affymetrix arrays, HG-
U133A and HT_HG-U133A, were used in CMap expression profiling and the RMA-normalized 
expression matrices from each chip type were merged into a single expression matrix. At this point, 
rows in the expression matrix are labelled ‘probe ID’, and columns are labelled with the name of 
the treatment drug. One column is referred to as one drug-treated sample. Boxplots obtained from 
the merged expression matrix before and after quantile normalization are shown in figure 4.8. 
Quantile normalization of the merged expression matrix was performed using the “LIMMA” 





































Figure 4.8 Boxplots of merged expression data frames before and after quantile normalization. (a) 





The boxplot of the merged expression matrix displays a clear separation of spread, position, and 
distribution of intensities between the two chip types (figure 4.8 a). However, after quantile 
normalization (figure 4.8 b), consistency between arrays is achieved. 
 
4.6 Batch effect detection 
Batch effects are potential limitations of the use of transcriptomic datasets such as those found in 
the CMap database. Gene expression level changes due to treatment with a drug may be 
confounded by uncontrolled variables such as cell culture conditions and batch handling by the 
experimenter. Cell lines that are treated with the same drug in different batches may result in 
greater batch variation in expression levels and less so in drug action (Newton et al., 2001). Thus, 
batch effects must be detected before proceeding with statistical analyses, and if batch effects are 
present, these must be removed in controlled ways. The next few paragraphs describe how batch 
effects in the expression matrix were detected using PCA and how these were removed using the 
“ComBat” package in Bioconductor. PCA plots were used to display both expression matrices 
before and after batch effect removal. 
 
4.6.1 Principle component analysis 
PCA is a useful exploratory data analysis visualization tool that helps to reduce data dimensionality 
while still retaining much of variability in the data. PCA can also identify useful patterns in the 
data. 
Drug-treated samples from the merged expression matrix in section 4.5.2.2 were grouped 
according to corresponding batch IDs. The samples were divided into two clusters after batch 
grouping, and the two clusters were labelled with the letter “A” and “B”, respectively. Samples 
from batch cluster A were labelled with red and cluster B with black. PCA was performed using 
the “prcomp” function from the Stats package in RStudio. The first PCA plot for batch effects 











Figure 4.9 PCA plot of the merged expression matrix for detection of batch effects. Each cross in the 
plot represents a drug-treated expression sample. The red crosses represent batch cluster A samples 
and the black crosses represent batch cluster B samples, with x- and y-axes representing principal 
component scores. 
 
PCA identifies linear combinations of variables such as probes and genes that explain the greatest 
variation in the data (Raychaudhuri et al., 1999). Typically, in gene expression analysis, PCA plots 
display how much influence each of the sample attributes selected from the linear combinations of 
variables has on the gene expression profile. Since the merged expression matrix was grouped by 
batch IDs and divided into two clusters using colour codes, if the plot separates expression samples 
into different clusters with corresponding colour, this probably indicates that the largest source of 
variation in the expression data is due to batch effects. In this case, figure 4.9 clearly displays a 
separation of samples into two batch clusters with some outliers. This indicates that the largest 
source of variation from the merged expression matrix was due to batch effects and these must be 
removed. 
 
4.6.2 ComBat analysis 
Batch effects were identified in the merged expression matrix as shown in figure 4.9. Batch effects 
were removed from the expression matrix using the “ComBat” function in the “sva” package in 
Bioconductor. “ComBat” allows users to adjust for batch effects in datasets in which the batch 
covariate is known, using methodology described by Leek et al. (Leek, Johnson, Parker, Jaffe, & 
Storey, 2012). It uses either parametric or non-parametric empirical Bayes frameworks to correct 
batch effects in datasets (Leek et al., 2012). After running ComBat analysis on a cleaned and 
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normalized expression matrix, the batch effect-corrected expression matrix was returned. This was 
visualized using PCA by once again selecting variables that explain the greatest variation in the 








Figure 4.10 PCA plot of the expression matrix corrected for batch effects using ComBat analysis 
from the sva package in Bioconductor. The x- and y-axes represent principal component scores. 
 
The PCA plot in figure 4.10 clearly displays clustering of two color-coded batch clusters with 
some outliers. This indicates that the largest source of variation is no longer related to batch effects. 
The batch effect-adjusted expression matrix returned can now be used for gene name annotation 
and subsequent statistical analyses. The pre-processing of expression data ends after batch effect 
correction. 
 
4.7 Gene annotation and glycosyltransferase gene retrieval 
The pre-processed numerical gene expression matrix contains 22,215 rows labelled with 
Affymetrix probe set IDs, and 203 columns corresponding to drug-treated samples. Each probe set 
ID must be annotated with its corresponding gene symbol. An annotation information file was 
generated using annotation libraries “hgu133a.db” and “hthgu133a.db” for chip types HG-U133A 
and HT_HG-U133A, respectively, in RStudio. When transforming probe set IDs to gene level data, 
some genes were represented by several probes set IDs, thus their mean intensities were used. 
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Since the U133A chip contains numerous genes with duplicated probe sets, this step was necessary 
and probes not matching gene names were discarded. 
A set of 210 GT genes was retrieved from the carbohydrate-active enzymes (CAZy) database 
(http://www.cazy.org). The CAZy database contains detailed classification and related information 
about enzymes involved in carbohydrate biosynthesis, metabolism, and transportation. All 210 GT 
genes were identified from the pre-processed expression matrix, which can now be used to perform 
statistical analyses such as differential expression analysis to identify differentially expressed GT 
genes in each drug treatment case. 
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5 DIFFERENTIAL GENE EXPRESSION AND CO-EXPRESSION 
MODULE ANALYSIS 
 
5.1 Microarray data analysis overview 
The previous chapter described data preparatory steps for gene expression analysis. The raw 
expression data was collected and pre-processed. The resulting output is a gene expression matrix 
and the probe set IDs were annotated with gene names. The columns have drug treatment names 
and the rows have the gene names. Each drug treatment case had 5 drug treated samples and 5 
untreated control samples. Where statistically required, some control samples were shared with 
amongst treated drug samples for consistent analysis. For instance, Alpha-estradiol and 
Alvespimycin shared common control sample. A standard R statistics package was used to build 
several design and contrast matrices and the LIMMA package from the Bioconductor was used to 
perform differential gene expression analysis. 
A rank sum test was performed to investigate statistically significant drug treatment cases where 
the GT genes were differentially regulated compared with non-GT genes (Smyth, 2005) upon 
exposure to drug treatment. Visual data analytics such as Heatmaps were used to separate up from 
down regulated GT genes derived from the relative expressions for each drug treatment case. 
Following this, a co-expression module analysis was performed. The WGCNA package from the 
Bioconductor was used to identify significant modules of genes that are co-expressed from the 
selected drug treatment case from the rank sum meta-analysis. Finally, gene ontology analysis of 
the co-expressed modules was done to identify significantly enriched functional biological process 
of the co-expressed modules to draw conclusions. The analyses reported here were performed in 
an R (version 3.3.3) statistical programming environment via RStudio using the Bioconductor 
packages as detailed in chapter 2 section 2.3.3. An overall schematic view of microarray data 
























Figure 5.1 Schematic view of microarray data analysis process using CMap expression data. 
 
5.2 Differential gene expression analysis 
The main goal of a class comparison strategy from microarray data analysis is to identify and select 
the genes that have expression levels that are significantly different between contrasting 
experimental conditions. These genes are aptly defined as “differentially expressed genes”.  
(Sánchez & de Villa, 2008) In the present study, genes that have a different expression level after 
drug treatment of a cell line compared to their expression in the case of no drug treatment are 
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defined as differentially expressed genes. Although this definition may appear trivial, there are 
several statistical measures that must be met for genes to be defined as differentially expressed. 
The methods and measures used to identify the differentially expressed genes for each drug-treated 
case from the pre-processed CMap gene expression matrix is detailed in this chapter within the 
framework of the LIMMA package. (Quackenbush, 2002)  
 
5.2.1 LIMMA approach 
LIMMA is a software package using linear models to analyse microarray gene expression data 
especially the analyses of designed experiments and the assessment of differential expression. 
LIMMA provides powerful means to simultaneously analyse contrasts between numerous RNA 
targets in designed experiments. LIMMA also offers an empirical Bayesian approach to produce 
stable results with a small number of sample replicates. (Ritchie et al., 2015) 
The use of LIMMA was discussed in detail in chapter 2. There it was pointed out that a numerical 
gene expression matrix and one or two experimental design specific matrices are required for this 
analysis. First, a design matrix, that details the specific treatment sample relationships must be 
constructed. Second, a contrast matrix, that specifies which comparisons must be made between 
the expression samples is built. LIMMA then makes possible the fitting of gene-wise linear models 
which is used to estimate log-intensities between target RNA samples simultaneously to identify 
differentially expressed genes. Once the linear model is fitted using a constructed design matrix, a 
contrast matrix is used to compute log2 fold changes and finally t-statistics, allowing pairwise 
comparisons between the contrasts of samples of interest, are made. (Ritchie et al., 2015) (Smyth, 
2005) 
 
5.2.2 Design matrix 
A design matrix was created using “model.matrix” function from the standard statistics package 
in R for all 29 drugs from the gene expression matrix. Both treatment and control samples were 
considered during the design matrix construction. The 203 representing total number of samples 
in the data as mentioned earlier, some drug-treatment samples shared a common control sample, 
that resulted in total number of treatment and control sample pair for 29 drugs of 42 (not 58). The 
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dimension of the design matrix was therefore 210x42 to which a linear model was fitted to the 
expression data. 
 
5.2.3 Linear model fitting 
Multiple linear models from generalized least squares were fitted using the “lmFit” function 
(LIMMA package). A linear model was fitted to a series of samples for each gene taken from each 
one of the 29 drug treatment cases. Following this linear fit coefficients, residuals, covariant 
coefficients and standard deviations were used to describe the differences between the RNA 
samples hybridized to the arrays. (Ritchie et al., 2015) 
 
5.2.4 Contrast matrix 
After a linear model was fitted for each gene across the samples the “makeContrasts” function was 
used to construct a contrast matrix that generates contrasts between a set of parameters in a numeric 
matrix. The parameters are represented by the coefficients from linear model fit. The contrast 
matrix reveals the comparisons that are made between the coefficients and the coefficients that are 
extracted from the linear model fit. (Ritchie et al., 2015) (Smyth, Ritchie, Thorne, & Wettenhall, 
2005) In this study, the contrast matrix was constructed for drug-treated samples and control 
samples. For example, in the Alpha-estradiol treatment, the contrast names were defined as 
“Alpha-estradiol” and “MCF-7 control”. This was the case for all 29 selected drugs. The contrasts 
from the linear model fit was computed using the “contrasts.fit” function and the fitted model 
object, from the coefficient of the design matrix, was re-oriented to the corresponding set of 
contrasts of the original coefficients following Smith et al.’s protocol. (Smyth et al., 2005) 
 
5.2.5 Empirical Bayes fit 
To statistically assess the differential gene expression, LIMMA uses a parametric empirical Bayes 
method (described in chapter 2) to moderate the standard errors of the estimated log-fold changes 
that results in i) more stable and robust inference and ii) improved power in analysis for a small 
number of samples. (Smyth, 2004) (Phipson, Lee, Majewski, Alexander, & Smyth, 2016) Here the 
function “eBayes” was used to compute moderated t-statistics, moderated F-statistics, and log-
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odds of differential expression. Various coefficients were returned as output values. The empirical 
Bayes adjusted expression matrix with contrast design was then available to extract the top most 
differentially expressed genes. 
 
5.2.6 Extraction of top differentially expressed genes 
The “topTable” function was applied to identify differentially expressed genes for each linear 
model fitted to the 29 drug treatment contrast case. A table of top-ranked differentially expressed 
genes from the linear model fit and various design and contrast matrices were then extracted by 
tuning the “topTable” function settings which we describe here. 
The function returns log2 FC (fold change), average expression values, moderated t-statistics, p-
value, adjusted p-value and B statistics in its output. The log2 FC value is an estimate of the log2-
fold-change that corresponds to the contrast value (see section 5.2.4). The average expression 
returns the i) average log2-expression for the probe over all sample arrays, ii) the raw p-values, iii) 
the false discovery rate (FDR) adjusted p-values and iv) the B statistics which is a log-odds that 
the gene is differentially expressed. Controlling the FDR as described in chapter 2 is essential for 
multiple hypothesis testing analyses such as differential gene expression analysis. The p-values 
for the contrast of interest were adjusted for multiple testing (using “p.adjust” in R) and the 
Benjamini & Hochberg method was used to control the expected FDR below the specified value. 
The threshold of adjusted p-value < 0.05 and |log2 FC (fold change) | > 0 and log2 FC < 0 were set 
to maximize the output of the differentially expressed genes in so doing improving the precision 
of gene selection. The genes that fall into the log2 FC range from -0.5 to 0.5 show no difference 
in expression. However, when the expression meets the p-value cut off < 0.05, those genes are 
identified as differentially expressed. All genes whose expression levels met these requirements 
were selected for subsequent analysis. For each drug treatment case, the genes were divided into 
two modules. The differential genes with log2 FC < 0 were labelled down-regulated gene module 
and the differential genes with log2 FC > 0 were labelled up-regulated gene module. 
Overviewing, the entirety of the statistical analysis performed in this thesis it will become apparent 
that the analyse can be grouped into one of two phases. The aim of the first phase was to identify 
differentially expressed GT and non-GT genes from the drug treatments. The aim of the second 
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phase was to identify the drug treatment that significantly influenced the regulation of GT genes 
in comparison to non-GT genes using the results from differential expression analysis. Following 
the second phase a set of selected drugs is used to construct a gene co-expression network with 
gene modules to make an inference about biological functions associated with specific gene co-
expression modules. 
 
5.3 Identifying differentially expressed genes 
Following the protocol outlined above a set of differentially expressed genes was returned for all 
29 drug treatments. The specific choices for FDR control with a threshold of adjusted p-value < 
0.05, log2 FC > 0 and log2 FC < 0, 26 for the drug treatment cases gave statistically validated 
differentially expressed genes. Of the 26 drug treatment case with DEGs a subset of 19 drug 
treatment cases, produced DEG that included differentially expressed glycosyltransferase (GT) 
genes. The information listing the DEGs and differentially expressed GT genes for each drug 
treatment case is listed Table 5.1. 
Several cancer drugs, including breast cancer drugs were used in the CMap project. It was 
predicted that the anti-cancer drugs would generate the most DEGs because these drugs would 
suppress the cancerous genes also, these drugs were tested on MCF-7 breast cancer cell line and 
indeed, the most DEGs and differentially expressed GT genes were produced by the anti-cancer 
drug treatment. I now consider the three drugs that produced the largest DEGs and GT-DEGs. The 
largest number of differentially expressed genes (6066 DEGs) were retrieved following the 
Vorinostat drug treatment. This drug was originally developed as a histone deacetylase inhibitor 
(HDAC) for the treatment of cutaneous T-Cell Lymphoma (CTCL). In contrast the lowest DEGs 
resulted from pioglitazone and rosiglitazone treatment that are type II diabetes mellitus treatment 
drugs. While Vorinostat   was primarily designed for the treatment of CTCL its usage has been 
extended to the treatment of breast cancer. (Munster et al., 2011) (Luu et al., 2008). Second on the 
list is Trichostatin (TSA) which is an organic compound with that has been considered as a possible 
anti-cancer drug. TSA promotes over-expression of genes that initiate apoptosis in a cancer cell to 
slow down the cancer progression. (Drummond et al., 2005) Then in the list of high DEGs follows 
a group of chemically related drugs (Tanespimycin, Geldanamycin and Alvespimycin) that have 
been used as dual purpose antibiotics and cancer treatments. Unsurprisingly they yield the same 
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levels of differential expression. Tanespimycin is a derivative of the antibiotic geldanamycin that 
is used to treat young patients with leukaemia and other tumours. (Dimopoulos, Mitsiades, 
Anderson, & Richardson, 2011) Alvespimycin is a derivative of Geldanamycin and inhibitor of 
heat shock protein (HSP) 90 together with Monorden, that is used to treat solid tumours in various 
type of cancers. (Pacey et al., 2011) Tretinoin is an all-trans retinoic acid (ATRA) that is effective 
for the treatment of acute promyelocytic leukaemia. (Warrell Jr et al., 1991) 
Table 5.1 Differentially expressed GT and non-GT genes identified for each drug treatment. 
Drug Name DEGs identified GT genes identified 
Vorinostat   6066 75 
Trichostatin A 4920 60 
Geldanamycin 3339 37 
Alvespimycin 3155 37 
Tanespimycin 2695 27 
LY-294002 2540 31 
15-Delta Prostaglandin J2 2416 32 
Thioridazine 2156 17 
Fulvestrant  1903 16 
Monorden   1749 19 
Sirolimus 1711 17 
Trifluoperazine 1434 16 
Monastrol 1271 15 
Tretinoin 1236 13 
Wortmannin 1152 11 
Prochlorperazine 1147 12 
Fluphenazine 692 4 
Genistein 157 3 
Estradiol 49 1 
Valproic Acid 15 0 
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Alpha-estradiol 19 0 
Troglitazone 9 0 
Rosiglitazone 0 0 
Pioglitazone 1 0 
Nordihydroguaiaretic Acid 0 0 
Clozapine 0 0 
Chlorpromazine 2 0 
Acetylsalicylic Acid (Aspirin) 8 0 
Haloperidol 13 0 
 
Finally closing out the list of high DEGs is LY-294002, an inhibitor of phosphoinositide 3-kinases 
(PI3Ks), a group of enzymes that are involved in the regulation of numerous cellular functions. 
LY-294002 has been identified as an effective anti-cancer agent (Maira, Stauffer, Schnell, & 
García-Echeverría, 2009). 15-Delta Prostaglandin J2 is a subset of prostaglandins (PGs) that exerts 
diverse biological functions, such as suppression of inflammation responses, growth, and survival 
of cells. 15-Delta Prostaglandin J2 has been identified and modelled for the development of novel 
anti-cancer drugs. (Wang & DuBois, 2006) (Clay, Monjazeb, Thorburn, Chilton, & High, 2002) 
Interestingly much further down the list (Table 5.1). Fulvestrant  is not in the group of high DEGs 
and GT-DEGs although it was designed to treat hormone receptor (HR)-positive metastatic breast 
cancer in postmenopausal women with disease progression and is widely used in clinical treatment. 
(Lee, Goodwin, & Wilcken, 2017) Another breast cancer drug that is not in the high DEGs set is 
Wortmannin. This is a steroid metabolite that is an inhibitor of PI3Ks and is known to inhibit a 
proliferation of MCF-7 breast cancer cell lines. (Karve et al., 2012) (Yun et al., 2012) Bottoming 
out the list is another cancer drug Genistein. This drug is an isoflavone that is both an antioxidant 
and anthelmintic, that has been tested and used as an effective in the treatment of prostate cancer. 





Table 5.2 An output of differential gene expression analysis from Vorinostat treatment displaying 
top 5 up and down regulated GT genes. 





NEU1 1.7985 8.4820 22.6399 9.1086e-54 1.1328e-51 
EXTL2 1.4230 6.7741 16.8145 2.5692e-38 9.2084e-37 
FUCA1 1.2590 8.3014 18.9469 3.5853e-44 2.0360e-42 
C1GALT1 1.0925 6.3813 14.2090 6.3511e-31 1.2970e-29 




ST6GALNAC -1.3139 7.8520 -16.0120 4.6106e-36 1.3884e-34 
B3GALNT1 -1.2487 8.4222 -13.1294 8.1344e-28 1.3435e-26 
PIGB -0.9447 7.1891 -11.6572 1.3964e-23 1.6780e-22 
ST3GAL1 -0.7697 6.3247 -6.8084 1.5340e-10 7.4965e-10 
MAN2A2 -0.7671 6.2627 -13.2427 3.8354e-28 6.4987e-27 
 
The drugs discussed above are primarily used to treat various type of cancers. Besides cancer drugs, 
some non-cancer drugs such as sirolimus and prochlorperazine interestingly produced a significant 
number of DEGs and differentially expressed GT genes. Given that Vorinostat tops the list with 
the most DEGs and DEG-GTs it appears as having the greatest potential to regulate the GT genes 
involved in breast cancer progression. It is worthwhile to consider a typical output of differential 
gene expression analysis (Table 5.2). 
 
5.4 Using meta-analysis to select effective breast cancer drugs 
While a simple numerical ranking of number of DEGs is appealing a more thorough approach is 
needed to select the drugs that have the most significant effect on changing the GT gene regulation 
from that of the untreated breast cancer cell line.  To achieve this a meta-analysis with two-groups 
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Wilcoxon rank sum test was performed using the raw p-values and gene expression matrices of 
the selected drug treatment obtained after differential expression analysis. Statistical methods we 
therefore used to investigate and select drugs that had greater influence on the regulation of GT 
genes (either up or down regulation) than on the regulation of non-GT genes. A subsequent 
visualization, co-expression module and gene ontology analyses were done based on the selected 
drugs. 
Meta-analysis is a statistical approach that systematically evaluates the pooled data from separate 
studies to measure for statistical significance that will point to unbiased. Typically, performing a 
differential gene expression analysis with a limited number of biological replicates would 
potentially increase the generation of false positives and this would lead to a misinterpretation of 
statistical significance. Including a meta-analysis step in the statistical workflow improves the 
robustness of the process and delivers greater reliability. (Allemeersch & Moreau, 2004) In this 
study it provides a greater confidence in the selection of drugs that are important in affecting GT 
gene regulation compared with the regulation of non-GT genes.  
A robust rank sum test in the form of meta-analysis to select drugs that had significant influence 
in the regulation of GT genes will now described. The test was performed using all the outputs of 
differential expression analysis of the 29 drug treatments and so overcoming the potential problem 
of a limited sample size in microarray data analysis. 
 
5.4.1 Two-groups Wilcoxon rank sum test 
A typical differential gene expression analysis would return several matrices containing 
information about the log2 FC (fold change), t-statistics, p-values and adjusted p-values for 
example as described in section 5.2.6 and the p-values returned is very useful for rank sum analysis. 
As previously stated the goal was to measure if GT genes are more significantly regulated in 
comparison to non-GT genes. Consequently, a ranking analysis of the GT and non-GT genes 
would be suitable for the comparison method. For this reason, a traditional non-parametric 
Wilcoxon rank sum test (also known as, Mann-Whitney U test) was used. (Troyanskaya, Garber, 
Brown, Botstein, & Altman, 2002) In this case only a two-group rank sum test was necessary since 
a rank comparison between the GT and non-GT genes were being made. The gene expression 
matrix after pre-processing had dimension of 22,215 by 203 as described in Chapter 4.  However, 
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after removal of the duplicated probe ID set representing a single gene name, the dimension of 
gene expression matrix was reduced to 12,436 by 203. All the subsequent meta-analysis used this 
reduced expression matrix.  
 
5.4.2 Methodology 
Initially, the gene expression matrix described (see section 5.3.1) was used to run a differential 
gene expression analysis. The analysis returned p-values as well as adjusted p-values in the output 
table. Since the aim was to rank the genes based on the p-values, a set of non-adjusted p-values 
were used to construct a p-values matrix for each drug treatment experiment. In total, 29 drug 
treatment p-values matrices were constructed, and they were merged into a single p-value matrix 
representing all 29 samples. Since there are 12,436 p-values, representing each gene and 29 drug 
treatment case (each drug treatment had 10 samples including treatment and control and this had 
gone through differential gene expression analysis) the dimension of the p-value matrix was 
12,436 by 29. 
Next, for each drug treatment, the p-values matrix was divided into a p-value matrix for GT genes 
and p-value matrix for non-GT genes through data manipulation techniques. Since the number of 
GT genes were a lot less than the non-GT genes, random sampling of non-GT genes without 
replacement was used to select the number of non-GT genes that matched the number of GT genes. 
For instance, if there were 75 GT genes from the p-values matrix A, the same number of non-GT 
genes were selected using random sampling without replacement method out of all the non-GT 
genes. The randomly selected non-GT genes with its respective p-values together with the selected 
GT genes with its respective p-values were used to perform two-group Wilcoxon rank sum test 
that works out the rank of individual p-values and evaluates if the GT genes were significantly 
regulated in comparison to the non-GT genes by that specific drug treatment. The two-groups 
Wilcoxon rank sum test that required random sampling of non-GT genes was done 1,000 times for 
each drug treatment to increase the statistical significance. An R function was created to perform 




To better understand the process, a simple R function that performs random sampling and two-
groups Wilcoxon rank sum test between GT and non-GT genes is shown below. 
 
wilcox_function <- function(gt_matrix, non_gt_matrix) { 
# apply 1 to 29 for each sample in columns 
 gt <- gt_matrix[, 1] 
 # define an empty vector      
 m <- c() 
 # iterate over1000 times       
 for (i in 1:1000) {    
  # apply 1 to 29 for each sample in columns   
  non_gts <- non_gt_matrix[sample(1:nrow(non_gt_matrix), 143, replace = FALSE), 1]  
  rank_sum_result <- wilcox.test(gt, non_gts)  
  # extract p-values 
  rank_p_value <-  rank_sum_result$p.value 
  m <- c(m, rank_p_value) 
 } 
 # return a vector of 1,000 p-values from Wilcoxon rank sum test 
 return(m)  
} 
 
Typically, the two-groups Wilcoxon rank sum test returns p-value for the rank sum test and if the 
p-value of the test returned is less than a decided threshold, for instance, p-value < 0.05, the test is 
deemed significant, and the null hypothesis of “GT genes are not significantly regulated by the 
drug” will be rejected. This implies that the drug treatment has had a significant effect on the 
regulation of the GT genes than on the non-GT genes. This protocol made possible a selection of 
drug treatments that had greatest effect in the GT genes. These were then used for co-expression 
module and gene ontology analysis to connect the treatment result with a molecule mechanism. 
















Figure 5.2 Schematic view of meta-analysis deploying two-groups Wilcoxon rank sum test. For each 
drug, x number of non-GT genes p-values were selected by random sampling 1,000 times. Two-
groups Wilcoxon rank sum test was performed 1,000 times between selected GT and non-GT p-values. 
 
5.4.3 Drug selection 
The drugs that had greatest effect in the regulation of GT genes were selected based on the 1,000 
p-values reported in the meta-analysis (section 5.3.2.). After a set of p-values were returned from 
meta-analysis of each drug, a histogram of the p-values was plotted for each drug. The distribution 
of the p-values was observed and the frequency of the p-values at different significance thresholds 
were observed. Threshold p-value < 0.05 was selected statistically significance. Thus, the more p-
values that were observed from the range 0 to 0.05 in the histogram, the more statistically 
significant the rank sum test was. Additionally, if the distribution of the histogram was skewed to 
the right, meaning each round of rank sum test produced lower p-values, the drug was considered 
to have had a significant effect on regulating the GT genes in comparison to the non-GT genes. 
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The drugs were selected based on two criteria. Firstly, the histogram’s distribution should have a 
skewness to the right and the frequency of p-values must be observed in the range 0 to 0.05 or at 
least those in the 0.1 region should be high. If this criterion is satisfied as a result of the two-groups 
rank sum test that was performed for 1,000 times for a drug treatment using randomly sampled 
non-GT genes, and the p-values observed were more in the significance threshold region, then it 
likely that the drug had a significant effect on the regulation of the GT genes. A second criteria is 
that the drug must have produced any differentially expressed genes (DEGs) as part of its output. 
If the drug did not produce any DEGs in the first place but showed significant regulation of GT 
genes from meta-analysis, this drug was not considered for subsequent co-expression and gene 
ontology module analysis. The two-groups Wilcoxon rank sum test results in the form of histogram 














Figure 5.3 Distribution of p-values obtained from the meta-analysis for cancer and non-cancer drugs. 
A significance threshold of p-value < 0.05 was selected for the Rank Sum Test. The drug selection 
was based on the distribution (in terms of skewedness) of the histogram and the frequency of p-value 






thioridazine and (e) trifluoperazine were selected for further analysis. The remaining histograms for 
another drug are available in the graph appendix B. 
 
The 29 different histograms were plotted for each drug treatment and through an inspection of p-
value distribution and frequencies 8 candidate drugs were selected to have a significant effect in 
the regulation of the GT genes, namely, Fulvestrant, Monorden, Nordihydroguaiaretic acid, 
Rosiglitazone, Thioridazine, Trifluoperazine, Troglitazone and Vorinostat. Of the 8 candidate 
drugs, only 5 were found to have produced any DEGs (see Table 5.1). These drugs were 
Fulvestrant, Monorden, Thioridazine, Trifluoperazine and Vorinostat. They were selected for 
subsequent analysis such as the co-expression module and gene ontology. Next the 5 drugs are 
considered in one of two groups either a cancer drug or non-cancer drug. 
 
5.4.3.1 Cancer drugs  
Remarkably 3 of the 5 drugs were existing cancer drugs that arose from their being selected based 
on their statistically significant performance following MCF-7 treatment that led to substantive 
altered regulation of GT genes compared with non-GT genes. The cancer drugs are Fulvestrant, 
Monorden, and Vorinostat. Fulvestrant is a medication used to treat hormone receptor (HR)-
positive metastatic breast cancer in postmenopausal women. (Nathan & Schmid, 2017) Monorden, 
also known as Radicicol is a substance that binds to heat shock protein 90 (HSP 90), which is a 
chaperon protein that stabilizes proteins involved in cancer tumour growth and altering its function. 
HSP 90 inhibitors are frequently studied and investigated as anti-cancer drugs because of its 
pharmacological inhibition ability in HSP 90. HSP 90 inhibitors have great potential as anti-breast 
cancer drug as they can suppress multiple oncogenic signalling pathways simultaneously. This 
effectively reduces possible molecular feedback loops and tumour resistance mutations. (Zagouri 
et al., 2013) As was mentioned previously Vorinostat is an immune system cancer drug that is a 
HDAC inhibitor used for treatment of CTCL. Of greater relevance here, Vorinostat has been well-
studied and investigated for breast cancer treatment because of its noted potential as an anti-breast 
cancer drug. (Munster et al., 2011) (Luu et al., 2008) 
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A heatmap is an effective visualization technique that is frequently used in genomic studies to 
visualize gene expression data. Here heatmaps displaying differentially expressed GT genes before 








































Figure 5.4 Heatmaps showing glycosyltransferase genes expression pattern before and after 
treatment of anti-cancer drugs on the MCF-7 breast cancer cell line. Each drug had (n = 10) samples 
in which 5 were treatment and the other 5 were control samples. Clear separation of up and down 
regulation of the genes can be identified from the heatmap visualization. (a) Fulvestrant treatment: 
left 5 are control and right 5 are treatment. (b) Monorden   treatment: left 5 are treatment and right 
5 are control. (c) Vorinostat   treatment: left 5 are treatment and right 5 are control. Expression 
profiles were clustered using hierarchical clustering with agglomeration method of “ward.D2”. 
 
The heatmaps of anti-cancer drugs show various differentially expressed GT genes regulation 
pattern. For instance, following Fulvestrant treatment, some important GT genes such as FUT4 
and B4GALT5 have been down-regulated after Fulvestrant treatment whereas, they were up-
regulated in MCF-7 cells without treatment. This was anticipated as Fulvestrant is a metastatic 




GT genes involved in breast cancer such as ST3GAL1 (see Figure 5.4 (b)). Studies have revealed 
that over-expression of ST3GAL1 promotes mammary tumorigenesis. (Picco et al., 2010) 
However, B4GALT5 which was down-regulated with Fulvestrant treatment was up-regulated with 
Monorden treatment. The Vorinostat treatment which generated the most differentially expressed 
GT genes (n = 75) results in the down-regulation of a number of different families of GT genes 
involved in breast cancer, such as FUT families and ST3GAL families. ST3GAL1 gene was up-
regulated in the MCF-7 cell line without treatment however, after Vorinostat treatment, it was 
down-regulated (Figure 5.4 (c)).  
 
5.4.3.2 Non-cancer drugs 
There were 2 non-cancer drugs namely, thioridazine and trifluoperazine. Both thioridazine and 
trifluoperazine are antipsychotic drugs primarily used to treat schizophrenia. (Hedberg, Houck, & 
GLUECK JR, 1971) (Overall, Hollister, Meyer, Kimbell, & Shelton, 1964) Some studies have 
used thioridazine and trifluoperazine to inhibit breast cancer growth. For instance, Wei et. al. (Wei, 
Hickie, & Klaassen, 1983) studied the effect of trifluoperazine on the growth of breast cancer cells 
and revealed in their in vitro study that trifluoperazine had the ability to inhibit the colony 
formation from the breast cancer cell line. (Strobl & Peterson, 1992) Further it was shown that 
thioridazine could utilize a distinct breast cancer pathway to inhibit the cell growth, leading to the 
conclusion that this is a potential noncytotoxic alternative to tamoxifen for treatment of tamoxifen-
































Figure 5.5 Heatmaps showing glycosyltransferase genes expression pattern before and after 





in which 5 were treatment and the other 5 were control samples. Clear separation of up and down 
regulation of the genes can be identified from the heatmap visualization. (a) Thioridazine treatment: 
left 5 are treatment and right 5 are control. (b) Trifluoperazine treatment: left 5 are treatment and 
right 5 are control. Expression profiles were clustered using hierarchical clustering with 
agglomeration method of “ward.D2”. 
 
Thioridazine drug unfortunately does not show a down-regulation of some of the ST3GAL family 
of genes including ST3GAL5 and ST3GAL1 and as well as members of the MGAT families 
including MGAT4A and MGAT2 genes. These genes were up-regulated after treatment of 
thioridazine. Surprisingly the FUT4 gene is down-regulated after thioridazine treatment, though in 
one sample, it has been up-regulated. This probably would indicate that thioridazine may not be 
an effective treatment for breast cancer since it did not down-regulated some of the important GT 
genes involved in breast cancer proliferation. Trifluoperazine’s effectiveness in breast cancer 
suppression is also questionable judging from the heatmap in figure 5.5 (b). GT genes such as 
NEU1, ST3GAL5, MGAT5 have all been up-regulated after the treatment. Although a few genes 
such as FUT8 and B4GALT2 have shown down-regulation pattern after treatment, in some 
samples, they have been up-regulated and this could indicate that trifluoperazine may not be the 
most effective treatment for breast cancer. It is expected that if the treatment was effective, across 
all 5 samples, the tumour cells should have same expression patterns as normal breast cells, but 
this was not the case in trifluoperazine treatment. 
 
5.5 Co-expression analysis 
Next a search for clues to GT gene biological function is undertaken through co-expression gene 
module analysis using the Weighted Gene Co-Expression Network Analysis (WGCNA) method.  
The co-expressed modules of genes are identified, and they are associated with specific biological 
processes through a gene ontology analysis. Attention is paid to GT genes that were up and down-
regulated after specific drug treatment and identified in a co-expressed module in so doing 
revealing the biological process with which that module associated with. From this analysis it is 
hoped that an insight into how the GT genes that are co-express with other genes including 
oncogenes to regulate a specific biological function in the development of tumour cells. Gene co-
expression network analysis aim to identify modules of genes that show a coordinated expression 
pattern based on a pairwise correlations between genes. (van Dam, Võsa, van der Graaf, Franke, 
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& de Magalhães, 2017) The WGCNA, a widely used systems biology method was used to 
construct a scale-free network from gene expression data of selected drug treatment from section 
5.3.3. The next few paragraphs describe how WGCNA was performed on the selected drug 
treatment to identify co-expressed modules of genes for subsequent gene ontology analysis. 
 
5.5.1 Weighted gene co-expression network analysis approach 
The WGCNA was performed using all the differentially expressed genes (DEGs) from section 
5.2.7 for drugs selected in section 5.3.3. Performing WGCNA using the glycosyltransferase gene 
subset would not be appropriate approach since the sample size is too small compared to all the 
DEGs generated. The analysis was performed in R using the WGCNA package which comprises 
functions that perform a correlation network analysis to cluster similarly expressed genes into a 
module. 
Following the WGCNA best practices (Langfelder & Horvath, 2014), for each gene expression 
data from selected drugs, the genes with zero counts or low variance were removed using the 
goodSampleGenes function. The co-expression analysis was initiated by calculating Pearson’s 
correlation matrices for all pairs of genes. The correlation coefficient between gene m and gene n 
was defined as Smn = |cor(m,n)|. The soft thresholding power (β) was computed 
(pickSoftThreshold function). The model fitting of expression dataset to a scale free topology is 




















Figure 5.6 Network fitting to the scale-free topology accordingly to the parameter used in the soft-
thresholding. The linear model of the regression line, Soft.R.sq was 0.65 with chosen β = 4. 
 
According to figure 5.6, that represents soft thresholding linear model of the regression line, the 
power of 4 was chosen since it was the lowest power for which the scale free topology index 
reached 0.65 (red line). However, the author of WGCNA as a caveat mentions that sometimes 
scale free topology cannot be reached for reasonably low values of β due to severe array outliers 
or globally distinct groups of arrays that lead to strong correlation between the expression profiles 
(and very large co-expression modules). In this case, for an unsigned network, β of 6 used to obtain 
a scale-free network. (Langfelder & Horvath, 2008) (Langfelder & Horvath, 2014) Next, the 
Pearson’s correlation matrices were transformed into adjacency matrices by computing absolute 
value of pairwise Pearson’s correlation between gene expression profiles each raised to the soft 
threshold power of β = 6. The power function amn = power (Smn, β) = |Smn|β. The adjacency matrices 
were transformed topological overlap measure (TOM) similarity matrices that measures a gene 
pair connectivity. A measure of dissimilarity (1 – TOM) was used to identify the clusters. The 
dissimilarity adjacency was taken to perform hierarchical average linkage clustering based on 
topological overlap and this was used to identify gene co-expression modules that grouped genes 
with similar expression pattern. The dynamic tree cut function was used to identify each gene 
modules with a minimum module size of 30 to preserve normality distribution assumption. 
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(Oldham, Horvath, & Geschwind, 2006) (Guo, Xiao, Guo, Dong, & Chen, 2017) (Liu, Jing, & Tu, 
2016) The module tree diagram with eigengenes clustered, and a dendrogram with modules with 
a unique colour code assigned based on the module size were constructed. The same scale-free 
network construction approach above was used for all dataset from 5 drug treatment cases. The 
tree diagram and dendrogram were visualized for each drug treatment in figure 5.7 and the modules 






















































































































Figure 5.7 Identification of gene co-expression modules in MCF-7 after 5 different drug treatments 
via hierarchical average linkage clustering (Dynamic Tree Cut algorithm was used to identify 
modules. The identified modules are coded by unique colours. The dendrogram and tree diagram 
showing eigengenes clustering is also shown. (a) Fulvestrant treatment: 31 modules identified. (b) 
Monorden treatment: 28 modules identified. (c) Thioridazine treatment: 36 modules identified. (d) 





Using WGCNA package in R, the differentially expressed genes (DEGs) from 5 different drug 
treatments were analysed in terms of their co-expression pattern. The DEGs with similar 
expression pattern were assigned into modules via hierarchical average linkage clustering, and for 
each drug treatment, total number of modules (figure 5.7) were identified. The genes within each 
co-expressed module show high connectivity and correlation.  Finally, the Entrez IDs of the genes 
within each module were retrieved for subsequent gene ontology analysis to associate each co-
expressed module of genes to biological processes through enrichment test. 
 
5.6 Biological interpretation 
Once the Entrez ID of the genes were retrieved, functional enrichment analysis was performed for 
the selected drugs. The list of highly correlated co-expressed genes from 5.4.1 were retrieved from 
the modules generated in dendrogram, and they were related to functional annotation database 
such as Gene Ontology (GO). The purpose of GO functional annotation was to examine if the co-
expressed genes from the modules were significantly enriched or impoverished in specific 
biological processes or functions in the GO terms. For this purpose, only the 3 cancer drugs namely, 
Fulvestrant, Monorden and Vorinostat were considered as their applications in breast cancer 
treatment were more well-known than the 2 non-cancer antipsychotic drugs. The co-expressed 
gene modules from the 3 cancer drugs were annotated in terms of its biological functions through 
GO enrichment analysis and the genes that were up and down regulated from figure 5.5 after 
treatment were mapped onto their respective co-expressed modules. Some co-expressed modules 
that represent specific biological function had down-regulated GT genes as its one of the genes co-
expressed and some modules had up-regulated GT genes. 
 
5.6.1 Gene ontology enrichment analysis 
Functional annotation of the modules was done using “GO.db” annotation package which contains 
the latest version of gene ontologies database. The function, “GOenrichmentAnalysis” from the 
WGCNA package was utilized to perform GO enrichment analysis. The enrichment analysis 
function required Homo Sapiens organism database such as “org.hs.eg.db”, “AnnotationDbi” and 
“GO.db”. For each co-expression module, the various enrichment scores (p-value) was calculated 
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using Fisher exact test and the specified ontologies were returned accordingly. The GO enrichment 
result for the three cancer drugs were tabulated. 
Table 5.3 GO enrichment significantly associated with WGCNA modules from Fulvestrant treatment. 
Only the modules with either up or down regulated glycosyltransferase genes co-expressed with other 
genes have been recorded. GO term is represented for each module. 
Module No. of 
genes 





Regulatory region DNA binding (GO:0000975) 0.001068  
Up 
 







Positive regulation of neuron differentiation (GO:0045666) 0.005  
Down 
 





Regulation of hormone biosynthetic process (GO:0043269) 0.0003  










Glucocorticoid receptor binding (GO:0035259) 0.005 
Green Yellow 69 Regulation of protein complex assembly (GO:0043254) 0.0013 Up 
Light Green 53 Glycerophospholipid biosynthetic process (GO:0046474) 0.0032 Down 
Orange 40 Oligodendrocyte development (GO:0014003)  0.009 Down 
Purple 68 Positive regulation of transporter activity (GO:0032411) 0.006 Down 
Saddle Brown 38 Regulation of hydrogen peroxide-induced cell death 
(GO:1903205) 
0.003 Down 
Tan 69 T-cell activation involved in immune response 
(GO:0002286) 
0.003 Down 




Table 5.4 GO enrichment significantly associated with WGCNA modules from Monorden treatment. 
Only the modules with either up or down regulated glycosyltransferase genes co-expressed with other 
genes have been recorded. GO term is represented for each module. 










Immunoglobulin mediated immune response (GO:0016064) 0.0015  
Up 
 



























70 Positive regulation of ATPase activity (GO:0032781) 0.008 Down 
Midnight 
Blue 
59 Glucose import (GO:0046323) 0.003 Down 
Pink 77 Multicellular organism metabolic process (GO:0044236) 1.71e-05 Up 
Red 87 Hydrogen ion transmembrane transport (GO:1902600) 0.001 Down 
Royal Blue 44 Activation-induced cell death of T cells (GO:0006924) 0.001 Down 
Salmon 64 Nerve development (GO:0021675) 5.17e-05 Down 
Tan 64 Growth factor receptor binding (GO:0070851) 0.0004 Down 




Table 5.5 GO enrichment significantly associated with WGCNA modules from Vorinostat treatment. 
Only the modules with either up or down regulated glycosyltransferase genes co-expressed with other 
genes have been recorded. GO term is represented for each module. 





Bisque4 54 Ribosome biogenesis (GO:0042254) 0.001 Down 
Black 86 Regulation of cell division (GO:0051781) 0.0004 Down 
Blue4 32 Glycoprotein biosynthetic process (GO:0010559) 0.003 Down 
Brown 97 Nerve growth factor signalling pathway (GO:0038180) 0.003 Up 
Dark Red 65 Motor neuron apoptosis (GO:0097049) 0.001 Up 
Honeydew 42 RNA metabolic process regulation (GO:0051252) 0.005 Up 
Ivory 57 Regulation of cell cycle (GO:0051726) 0.001 Up 
Lavender 
Blush2 
42 Activated T cell proliferation (GO:0050798) 0.005 Down 
Light Coral 44 Positive regulation of small GTPase mediated signal 
transduction (GO:0051057) 
0.006 Down 
Light Cyan 70 Drug metabolic process (GO:0017144) 0.002 Down 
Light Green 70 Regulation of histone phosphorylation (GO:0033127) 0.001 Down 
Light Slate 
Blue 
36 Polyamine biosynthetic process (GO:0006596) 0.001 Down 
Light Yellow 68 Protein folding (GO:0006457) 0.003 Down 
Maroon 50 DNA replication initiation (GO:0006270) 0.001 Down 
Medium 
Orchid 
48 Epithelial structure assembly (GO:0010669) 0.001 Down 
Medium 
Purple1 
36 Cellular response to wortmannin (GO:1904568) 0.006 Down 
Medium 
Purple2 
45 Positive regulation of cytokine production in immune system 
(GO:0002720) 
0.003 Down 
Orange 62 Regulation of protein transport (GO:0051223) 0.001 Down 
Orange Red1 37 Glyceraldehyde-3-phosphate biosynthesis (GO:0046166) 0.006 Down 
Orange Red4 58 B cell apoptotic process (GO:0001783) 0.004 Down 
Pale Violet 
Red2 
43 Protein localization (GO:0034613) 0.001 Up 
Pale Violet 
Red3 
51 Negative regulation of DNA binding (GO:0043392) 0.0004 Down 
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Plum2 54 Regulation of cAMP biosynthetic process (GO:0030817) 0.00001 Up 
Plum3 44 Glucocorticoid catabolic process (GO:0006713) 0.007 Down 
Plum4 32 Regulation of gluconeogenesis involved in cellular glucose 
homeostasis (GO:0090526) 
0.005 Down 
Royal Blue 69 Polyamine biosynthetic process (GO:0006595) 0.005 Down 
Saddle Brown 61 Regulation of exocytosis (GO:0017157) 0.003 Up 
Sienna3 60 Glycosphingolipid biosynthetic process (GO:0006688) 0.005 Up 
Sky Blue 61 Cardiac right ventricle morphogenesis (GO:0003215) 0.004 Up 
Tan 80 Sodium channel activity (GO:0005272) 0.001 Up 
Thistle 43 Regulation of translation (GO:0006417) 0.006 Up 
Thistle1 53 T-cell migration (GO:0072678) 0.002 Up 
Thistle3 41 Cell surface pattern recognition receptor signalling pathway 
(GO:0002752) 
0.006 Down 
Violet 60 Transferase activity (GO:0016740) 0.002 Up 
Yellow 97 Antigen processing and presentation of peptide antigen 
(GO:0048002) 
0.002 Up 
Yellow3 39 Regulation of TORC1 signalling (GO:1904263) 0.0001 Down 
Yellow Green 59 Regulation of sodium ion transport (GO:0002028) 0.0002 Up 
 
The significantly enriched functions for co-expressed modules with up regulated GT genes in 
Fulvestrant drug treatment (Table 5.3) were mostly regulatory associated biological processes. 
Some modules with down regulated GT genes were involved in activation and biosynthesis 
processes. Fulvestrant is known to treat hormone receptor (HR)-positive metastatic breast cancer 
and identifying GT genes that are responsible for breast cancer metastasis in the co-expressed 
modules generated by Fulvestrant treatment would present valuable insight into breast cancer 
treatment strategy. The up and down regulated GT genes in the co-expressed gene module 
produced by Fulvestrant can be identified and their mechanisms of action can be further studied. 
Monorden drug treatment had a blue module with its co-expressed genes playing role in Wnt 
signalling pathways (Table 5.4) which is a pathway involved in carcinogenesis including breast 
and prostate cancers. The GT genes, MAN1B1 and ALG3 were involved in the blue module with 
Wnt signalling pathways and they were down regulated after treatment of Monorden. Turquoise 
module from Monorden treatment was significantly enriched in regulation of lymphocyte 
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activation with GCNT1 gene up regulated after treatment. Monorden   is an inhibitor of heat shock 
protein 90 (HSP 90 stabilizes proteins involved in cancerous tumour growth) that has great 
potential as breast cancer treatment drug as they can suppress multiple oncogenic signalling 
pathways simultaneously as described in section 5.3.3.1. Indeed, one of the co-expressed modules 
was significantly enriched in Wnt signalling pathways and a few GT genes were down regulated 
in the co-expression module. Further research in the role of Monorden drug treatment in the 
specific module of co-expressed genes and GT genes within the module will be required to better 
understand how the GT genes and non-GT genes in the module co-express together to affect the 
breast cancer pathways. 
Vorinostat drug treatment generated the most co-expressed modules and many enriched biological 
functions from GO annotation were returned (Table 5.5). The blue4 module from Vorinostat   
treatment was significantly enriched in glycoprotein biosynthesis process and the GT gene within 
the module has been down regulated after treatment. The orange module was enriched in regulation 
of protein transport and it had down regulated GT genes. Most of the biosynthesis processes that 
were enriched in Vorinostat treated co-expressed modules had down regulated GT genes, whereas 
activities such as sodium channel activity, T-cell migration, transferase and sodium ion transport 
had up regulated GT genes. Interestingly, thistle3 module was significantly enriched in cell surface 
pattern recognition of receptor signalling pathway and the GTs were down regulated after 
treatment.  
After treatment with each of the three cancer drugs it has been shown here that they affect the 
biological functions associated with co-expression modules through alteration of the gene 
regulation in that module. The alteration of GT genes expression is of importance. These findings 
present useful insight into how the GT genes co-express with specific genes in a module to alter a 
biological function after treatment of specific cancer drugs. These findings could possibly be used 
in the future drug repurposing research and it is hoped that these results will aid in designing novel 
breast cancer therapeutic drugs. 
 
5.7 References 
1. Allemeersch, J., & Moreau, Y. (2004). Meta-analysis of microarrays.  
113 
 
2. Banerjee, S., Li, Y., Wang, Z., & Sarkar, F. H. (2008). Multi-targeted therapy of cancer by 
genistein. Cancer letters, 269(2), 226-242.  
3. Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H., & High, K. P. (2002). 15-Deoxy-Δ12, 14-
prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. Journal of 
lipid research, 43(11), 1818-1828.  
4. Dimopoulos, M.-A., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. (2011). 
Tanespimycin as antitumor therapy. Clinical Lymphoma, Myeloma and Leukemia, 11(1), 17-22.  
5. Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005). 
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. 
Pharmacol. Toxicol., 45, 495-528.  
6. Guo, X., Xiao, H., Guo, S., Dong, L., & Chen, J. (2017). Identification of breast cancer 
mechanism based on weighted gene coexpression network analysis. Cancer gene therapy.  
7. Hedberg, D. L., Houck, J. H., & GLUECK JR, B. C. (1971). Tranylcypromine-trifluoperazine 
combination in the treatment of schizophrenia. American Journal of Psychiatry, 127(9), 1141-
1146.  
8. Karve, S., Werner, M. E., Sukumar, R., Cummings, N. D., Copp, J. A., Wang, E. C., . . . Pacold, 
M. E. (2012). Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. 
Proceedings of the national academy of sciences, 109(21), 8230-8235.  
9. Langfelder, P., & Horvath, S. (2008). WGCNA: an R package for weighted correlation network 
analysis. BMC bioinformatics, 9(1), 559.  
10. Langfelder, P., & Horvath, S. (2014). Tutorials for the WGCNA Package. 
11. Lee, C. I., Goodwin, A., & Wilcken, N. (2017). Fulvestrant for hormone‐sensitive metastatic 
breast cancer. The Cochrane Library.  
12. Liu, J., Jing, L., & Tu, X. (2016). Weighted gene co-expression network analysis identifies 
specific modules and hub genes related to coronary artery disease. BMC cardiovascular 
disorders, 16(1), 54.  
13. Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., . . . Gandara, D. R. 
(2008). A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast 
cancer: a California Cancer Consortium study. Clinical Cancer Research, 14(21), 7138-7142.  
14. Maira, S.-M., Stauffer, F., Schnell, C., & García-Echeverría, C. (2009). PI3K inhibitors for cancer 
treatment: where do we stand? : Portland Press Limited. 
15. Munster, P., Thurn, K., Thomas, S., Raha, P., Lacevic, M., Miller, A., . . . Moasser, M. (2011). A 
phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the 
114 
 
treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer, 
104(12), 1828.  
16. Nathan, M. R., & Schmid, P. (2017). A Review of Fulvestrant in Breast Cancer. Oncology and 
therapy, 5(1), 17-29.  
17. Oldham, M. C., Horvath, S., & Geschwind, D. H. (2006). Conservation and evolution of gene 
coexpression networks in human and chimpanzee brains. Proceedings of the national academy of 
sciences, 103(47), 17973-17978.  
18. Overall, J. E., Hollister, L. E., Meyer, F., Kimbell, I., & Shelton, J. (1964). Imipramine and 
Thioridazine in Depressed and Schizophrenic Patients: Are there specific antidepressant drugs? 
JAMA, 189(8), 605-608.  
19. Pacey, S., Wilson, R. H., Walton, M. I., Eatock, M., Hardcastle, A., Zetterlund, A., . . . Roels, B. 
(2011). A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given 
intravenously to patients with advanced, solid tumors. Clinical Cancer Research, clincanres. 
1927.2010.  
20. Phipson, B., Lee, S., Majewski, I. J., Alexander, W. S., & Smyth, G. K. (2016). Robust 
hyperparameter estimation protects against hypervariable genes and improves power to detect 
differential expression. The annals of applied statistics, 10(2), 946.  
21. Picco, G., Julien, S., Brockhausen, I., Beatson, R., Antonopoulos, A., Haslam, S., . . . Taylor-
Papadimitriou, J. (2010). Over-expression of ST3Gal-I promotes mammary tumorigenesis. 
Glycobiology, 20(10), 1241-1250.  
22. Quackenbush, J. (2002). Microarray data normalization and transformation. Nature genetics, 32, 
496.  
23. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). limma 
powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic 
acids research, 43(7), e47-e47.  
24. Sánchez, A., & de Villa, M. (2008). A tutorial review of microarray data analysis. Universitat de 
Barcelona.  
25. Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Statistical applications in genetics and molecular biology, 
3(1), 1-25.  
26. Smyth, G. K. (2005). Limma: linear models for microarray data Bioinformatics and 
computational biology solutions using R and Bioconductor (pp. 397-420): Springer. 
115 
 
27. Smyth, G. K., Ritchie, M., Thorne, N., & Wettenhall, J. (2005). LIMMA: linear models for 
microarray data. In Bioinformatics and Computational Biology Solutions Using R and 
Bioconductor. Statistics for Biology and Health.  
28. Strobl, J. S., & Peterson, V. A. (1992). Tamoxifen-resistant human breast cancer cell growth: 
inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. Journal of 
Pharmacology and Experimental Therapeutics, 263(1), 186-193.  
29. Troyanskaya, O. G., Garber, M. E., Brown, P. O., Botstein, D., & Altman, R. B. (2002). 
Nonparametric methods for identifying differentially expressed genes in microarray data. 
Bioinformatics, 18(11), 1454-1461.  
30. van Dam, S., Võsa, U., van der Graaf, A., Franke, L., & de Magalhães, J. P. (2017). Gene co-
expression analysis for functional classification and gene–disease predictions. Briefings in 
bioinformatics, bbw139.  
31. Wang, D., & DuBois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115-122.  
32. Warrell Jr, R. P., Frankel, S. R., Miller Jr, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. 
N., . . . Jakubowski, A. (1991). Differentiation therapy of acute promyelocytic leukemia with 
tretinoin (all-trans-retinoic acid). New England Journal of Medicine, 324(20), 1385-1393.  
33. Wei, J.-W., Hickie, R. A., & Klaassen, D. J. (1983). Inhibition of human breast cancer colony 
formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer chemotherapy and 
pharmacology, 11(2), 86-90.  
34. Yun, J., Lv, Y., Yao, Q., Wang, L., Li, Y., & Yi, J. (2012). Wortmannin inhibits proliferation and 
induces apoptosis of MCF-7 breast cancer cells. European journal of gynaecological oncology, 
33(4), 367-369.  
35. Zagouri, F., Sergentanis, T. N., Chrysikos, D., Papadimitriou, C. A., Dimopoulos, M.-A., & 
Psaltopoulou, T. (2013). Hsp90 inhibitors in breast cancer: a systematic review. The Breast, 







6 CONCLUSIONS AND FUTURE WORK 
 
Gene expression technology combined with bioinformatics applications can be used to study the 
effect of different therapeutic drugs on breast cancer cells. The examination of gene expression 
patterns after various drug treatments provides a better understanding of how a specific drug can 
affect the regulation of critical genes that play significant roles in breast cancer proliferation. 
The first task of the present work involved obtaining raw gene expression data from the CMap 
database. The expression data used were generated from microarray technology and consisted of 
MCF-7 breast cancer cell samples treated with 29 different therapeutic drugs, including anticancer 
and non-cancer drugs. Several pre-processing steps were followed, including data cleaning, quality 
checking, normalization, and batch effect removal, to obtain a gene expression matrix for 
differential expression and co-expression analysis. 
Differential gene expression analysis was performed based on the reliable gene expression matrix 
obtained previously, and drug-treated samples with DEGs were filtered using several statistical 
protocols. To perform a more robust analysis, a two-group Wilcoxon rank sum meta-analysis was 
performed based on the previously selected samples to identify drug candidates that had a 
significant effect on the regulation of GT genes. Three anticancer drugs, including Fulvestrant, 
Monorden, Vorinostat, and the two antipsychotic drugs trifluoperazine and thioridazine, passed 
the rank sum test. A set of GT genes was identified, and their expression patterns were visualized 
as heatmaps. 
Finally, the WGCNA method was applied to the five drugs selected to identify co-expressed gene 
modules. Various co-expressed modules were identified for each drug and the three anticancer 
drugs were then selected for subsequent GO enrichment analysis to correlate co-expressed 
modules with biological functions. The co-expression modules were selected based on the 
presence of up- or down-regulated GT genes in the module. For each drug treatment, a number of 
different modules with associated biological functions were identified. Fulvestrant treatment 
generated co-expressed modules that were involved in biosynthesis, transportation regulation, and 
apoptosis. Monorden treatment generated co-expressed modules that were involved in the Wnt 
signalling pathway, which is an oncogenic cancer signalling pathway. Interestingly, some of these 
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GT genes were down-regulated, suggesting a possible interaction between GT and other genes in 
this co-expression module, acting to suppress this cancer signalling pathway. Monorden could 
therefore be effective in breast cancer treatment. Vorinostat treatment generated co-expression 
modules that were involved in glycoprotein biosynthesis, protein transportation, and cell surface 
pattern recognition for receptor signalling pathways. The GT genes involved in these biological 
functions were down-regulated after Vorinostat treatment. 
The most important limitation of this research is the insufficient number of biological replicates to 
enhance the statistical significance of analyses and generate more reliable and robust results. For 
a typical gene expression analysis, not enough replicates were used in this study. To overcome this 
challenge to some extent, an additional meta-analysis incorporating a two-group Wilcoxon rank 
sum test was performed. The usage of Wilcoxon rank sum test removed the bias of selecting small 
number of replicates in this study. However, in the future, incorporation of a greater number of 
biological replicates would doubtless improve the study and generate more reliable results. 
The methods used here to identify specific DEGs and DCMs along with their enriched biological 
functions will provide useful insight into future drug repurposing strategies to develop novel 
therapeutic drug candidates that will target specific genes and pathways in human breast cancer. 
In terms of future work, further study of DEGs involved in co-expressed modules and their 
annotated biological functions would be needed, and an in-depth pathway analysis of the genes 
and co-expressed modules identified may contribute to the greater understanding of breast cancer 
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review of microarray data analysis” [accessed on 16th February 2018]. Reprinted from the 
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permission in these cases: materials with free licenses, generally, you can use any material that 
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Figure 2.6 - * Permission to reproduce this figure has been granted by the author of “WGCNA: 
An R package for weighted correlation network analysis” [accessed on 20th February 2018]. 
Reprinted from the paper’s copyright section: “© Langfelder and Horvath; licensee BioMed 
Central Ltd. 2008. This article is published under license to BioMed Central Ltd. This is an Open 
Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited.” 
 
Figure 2.7 - * Permission to reproduce this figure has been granted by the author of 
“Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large 
gene lists” [accessed on 3rd March 2018]. Reprinted from the paper’s copyright section: 
“Copyright © 2008 The Author(s). This is an Open Access article distributed under the terms of 
the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial 
use, distribution, and reproduction in any medium, provided the original work is properly cited.” 
 
Figure 3.1 - * Permission to reproduce this figure has been granted by the author of “Essentials of 
Glycobiology” [accessed on 17th March 2018]. Reprinted from the copyright information: “Some 
of the content found in Bookshelf is authored and published by the National Center for 
Biotechnology Information (NCBI) or other institution of the U.S. government. No permission is 
needed to reproduce or distribute this type of content, but the authoring institute or agency must 
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Figure 3.2 - * Permission to reproduce this figure has been granted by the author of “Glycan 
profiling of adult T-cell leukemia (ATL) cells with the high-resolution lectin microarrays.” 
[accessed on 17th March 2018]. Reprinted from the paper’s copyright section: “© 2013 Iha and 
Yamada; licensee InTech. This is an open access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
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Appendix B: Additional charts and tables 
Figure 1: The remainder p-value distribution histograms obtained from the meta-analysis (Rank 





























































































Table 1: A list of 29 drugs that have passed the selection criteria. 
 
Drug Name Indication Target Protein Chemical Formula 
with PubChem CID 
Trichostatin A Cancer Histone Deacetylase (inhibitor) C17H12N2O3 / 
444732 
 
Vorinostat Cutaneous T-Cell 
Lymphoma 
Histone Deacetylase (inhibitor) C14H20N2O3/ 
5311 











Delta Isoform (inhibitor) 
C23H24O8/ 
312145 




Fulvestrant Breast Cancer Estrogen Receptor (antagonist) C32H47F5O3S/ 
104741 
Estradiol Urogenital Symptoms Estrogen Receptor (antagonist) C18H24O2/ 
5757 












5-HT Receptor (antagonist) C18H19CIN4/ 
2818 
Chlorpromazine Schizophrenia, Nausea 
and Vomiting 
5-HT2 Receptor (antagonist) C17H19CIN2S/ 
2726 















Tanespimycin Breast Cancer, 
Melanoma, Multiple 
Myeloma 










Alvespimycin Ovarian Cancer, Breast 
Cancer, Leukemia 










Alpha-estradiol Hair Loss Androgen Receptor (antagonist) C18H24O2/ 
68570 


























Tretinoin Acute Promyelocytic 
Leukemia 






Various Forms of Pain, 
Inflammation 
Cyclo-Oxygenase-1 (inhibitor) C9H8O4/ 
2244 




Genistein Prostate Cancer DNA Topoisomerase 2-alpha 
inhibitor, Estrogen Receptor 
C15H10O5/ 
5280961 
 
